Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
Meenhard Herlyn, D.V.M, D.Sc.
Updated: 3/1/14
Home Address
1223 Knox Road
Wynnewood, PA 19096
Office Address
The Wistar Institute
3601 Spruce Street
Philadelphia, PA 19104 USA
Tel.: 215-898-3950
Fax: 215-898-0980
Email: herlynm@wistar.org
Web: http://www.wistar.org/lab/meenhard-herlyn-dvm-dsc
EDUCATION
1970
1976
D.V.M., Veterinary Medical School, Hannover, Germany
D.Sc., Medical Microbiology, University of Munich, Germany
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS
1971-1972
Fellowship in Immunology and Virology, University of Munich, Germany
1972-1976
Assistant at the Institute of Medical Microbiology, Infectious and Epidemic
Diseases, Veterinary Faculty, Maximillian University, Munich, Germany
1976-1979
Associate Scientist, The Wistar Institute, Philadelphia, PA
1979-1981
Research Associate, The Wistar Institute, Philadelphia, PA
1981-1985
Assistant Professor, The Wistar Institute, Philadelphia, PA
1986-1990
Associate Professor, The Wistar Institute, Philadelphia, PA
1991-present
Professor, The Wistar Institute, Philadelphia, PA
1991-1993
Chairman, Program of Experimental Therapeutics, The Wistar Institute,
Philadelphia, PA
1993-1998
Chairman, Program of Molecular and Cellular Biology, The Wistar
Institute, Philadelphia, PA
1998-2002
Chairman, Tumor Biology Program, The Wistar Institute, Philadelphia, PA
2002-2012
Leader, Molecular and Cellular Oncogenesis Program, The Wistar
Institute, Philadelphia, PA
2008-2011
Associate Director for Translational Research, The Wistar Institute
2010-present
Director, Melanoma Research Center, Philadelphia, PA
2011-present
Caspar Wistar Professor in Melanoma Research, Philadelphia, PA
FACULTY APPOINTMENTS
1982-1996
Consultant, Adjunct Associate Professor of Gynecology, Adjunct Professor
of Gynecology, Dept. of Gynecology, Division of Surgery, University of
Texas, MD Anderson Cancer Center, Houston, TX
1989-1991
Wistar Institute Associate Professor of Dermatology and Wistar Institute
Associate Professor of Pathology and Laboratory Medicine, University of
Pennsylvania, Philadelphia
1989-present
Member, Cellular and Molecular Biology Graduate Program (CAMB),
University of Pennsylvania, Philadelphia
1
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
1991- present
1992-present
1995-2002
2007-present
2011-present
Member, University of Pennsylvania Comprehensive Cancer Center,
Philadelphia
Wistar Institute Professor of Dermatology and Wistar Institute Professor of
Pathology and Laboratory Medicine, University of Pennsylvania,
Philadelphia
Member, Institute for Human Gene Therapy, University of Pennsylvania,
Philadelphia
Member, Bioengineering Graduate Group, University of Pennsylvania,
Philadelphia
Member, Institute for Regenerative Medicine, University of Pennsylvania,
Philadelphia
AWARDS AND HONORS
2004
Wings of Hope, Melanoma Research Foundation Award
2004
Diana Ashby Award for Excellence in Melanoma Research
2005
American Skin Association Annual Skin Cancer/Melanoma Achievement
Award
2006
Scientific Research Award for Outstanding Contributions in Melanoma
Research, American Cancer Society, Southeast Region, Pennsylvania
Division
2006
7th Annual Wallace H. Clark, Jr., M.D. Lectureship in Cutaneous
Oncology, University of Pennsylvania, Philadelphia, PA
2007
Pan American Pigment Cell Society Achievement Award
2007
Lifetime Achievement Award in Melanoma Research, Society of Melanoma
Research
2008
28th Alfred-Marchioni Memorial Award, Hamburg, Germany
2008
Joseph-von-Plenck Award, Austrian Society for Dermatology and
Venereology, Vienna Austria
2010
Award for Lifetime Achievement in Melanoma Research, Society for
Melanoma Research
2013
Rod and Ceil Mortel Visiting Scholar in Cancer Research, Penn State Milton
S. Hershey Medical Center, Penn State College of Medicine, Hershey, PA
2013
Founders Award, Society for Melanoma Research
MEMBERSHIPS IN: PROFESSIONAL AND SCIENTIFIC SOCIETIES (including offices
held):
1982-present
American Association for Cancer Research
1996-2002, Pennsylvania Steering Committee
1997, Program Committee Chair, Biology
2004-2005, Stem Cell Initiative
1984-2010
American Association for Investigative Pathology
1995-present
Society for Investigative Dermatology
1999-present
Pan American Society for Pigment Cell Research
1999-2002, Council Member
1999-2002, Melanoma Group Chair
2000-2002, Membership Committee
1999-present
International Federation of Pigment Cell Societies
1999-2003, Special Interest Group on ‘Biology of Melanoma’ Chair
1985-present
American Association for the Advancement of Science
2000-present
Metastasis Research Society
2
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
2004-present
2006-2011
2010-present
Society for Melanoma Research
2004-2007, Founder and President
2004-2007, Ex officio member of Executive Committee, Steering
Committee (Chair), Meeting Committee, Finance Committee, Election
Committee, Membership Committee
2007-2010, Past President, Member Steering Committee
Society for Stem Cell Research
American Society for Clinical Oncology
EDITORIAL POSITIONS
Editorial Board, The Journal of Clinical Laboratory Analysis
1986-1988
Associate Editor, Melanoma Research
1990-present
Editorial Board, Cell Growth and Differentiation
1992-1998
Associate Editor, Pigment Cell Research
1994-1999
Associate Editor, Journal of Experimental Therapeutics and Oncology
1995-2003
Editorial Board, Pathology Oncology Research
1995-2002
Editorial Board, American Journal of Pathology
1997-2004
Editorial Board, Tumor Targeting
1998-2000
Editorial Board, Cancer Research
2000-2007
Editorial Board, Cancer Biology and Therapy
2001-present
Editorial Board, Cancer and Metastasis Review, 2005 Guest Editor
2002-present
Associate Editor, Journal of Investigative Dermatology
2002-2007
Associate Editor, Pigment Cell and Melanoma Research
2005-present
Editorial Board, International Journal of Cancer
2005-present
Section Editor, Journal of Investigative Dermatology
2007-present
Scientific Advisory Board, Journal of Cell Communication and Signaling
2007-present
Consulting Editorial Board, Journal of Clinical Investigation
2007-present
Editorial Board, Open Dermatology Journal
2007-present
Editorial Board, Journal of Oncology
2008-present
Editorial Board, Experimental Dermatology
2008-present
Editorial Board, Genes & Cancer
2009-present
Editorial Board, PLoS One
2010-2011
2012-present
Editorial Board, Cancer Biomarkers
2013-present
Editorial Board, Melanoma Management
2013-present
Editorial Board, Precision Oncology
2013-present
Advisory Board, International CCN Society
MANUSCRIPT REVIEWER
With major support from laboratory members, review of 110-170 manuscripts per year (2000present) for the American Journal of Pathology, Archives of Dermatology, Cancer, Cancer Cell,
Cancer Research, Cell, Clinical Cancer Research, Experimental Cell Research, International
Journal of Cancer, Journal of Cell Science, Journal of Clinical Investigations, Journal of
Investigative Dermatology, Journal of Immunology, Journal of Experimental Medicine,
Laboratory Investigation, Melanoma Research, Molecular Carcinogenesis, Nature, Nature Cell
Biology, Nature Medicine, Nature Review Cancer, Oncogene, Pigment Cell Melanoma
Research, Proceedings National Academy of Sciences (USA), and Science.
3
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
LECTURES BY INVITATION (past 5 years)
2009 Feb. 23
Melanoma Research Alliance
April 18
American Association for Cancer Research, Denver, CO
April 29
University of Wisconsin, Madison, WI
May 12
World Congress of Melanoma, Vienna, Austria, Keynote Lecture
May 20
Australian Congress of Dermatology, Brisbane, Australia,
Honorary Lecture
May 27
Rutgers University, Cancer Center Retreat, Keynote Lecture
June 23
University of Heidelberg, Germany
July 17
Mayo Clinic, Rochester, MN
Sept. 18
NCI, Frederick, MD
Oct. 9
European Academy for Dermatology and Venereology, Berlin,
Germany
Nov. 2
SMR 4th International Congress, Boston, MA
Nov.18
MD Anderson Cancer Center, Houston, TX
Nov. 20
Cancer Therapy, Havana, Cuba
2010
Jan. 11
Jan. 14
Feb. 23
March 2
March 31
April 30
May 28
June 2
June 24
June 26
August 2
Sept. 12
Nov. 2
Nov. 5
Nov. 9
Dec. 14
2011
Jan. 12
Jan. 28
Feb. 2
Feb. 18
March 7
March 23
April 2-4
April 27
May 5
May 25
June 27
University of Vienna, Vienna, Austria
L’Oreal, Paris, France
University of North Carolina, Chapel Hill, NC
University of Pittsburgh, Pittsburgh, PA
University of California at Irvine, Irvine, CA
Moffitt Cancer Center, Tampa, FL
Schering-Plough, Kenilworth, NJ
MD Anderson Cancer Center, SPORE Symposium, Houston, TX
GenoMEL, University of Leeds, Leeds, GB
Human Skin Carcinogenesis Symposium, Collegeville, PA
Roswell Park Memorial Institute, Buffalo, NY
AACR TME and Metastasis, Philadelphia, PA
Centenary Institute, University of Sydney, Sydney, Australia
SMR 7th International Conference, Sydney, Australia
Melanoma Symposium, Western Australia Institute for Medical
Research, Perth, Australia
University of Ohio, Cincinnati, OH
MD Anderson Cancer Center, Science Park, TX
L’Oreal, Paris, France
Adelson Medical Research Foundation, Las Vegas, NV
Melanoma Research Alliance, Washington, DC, Session Chair
AACR Special Conference on Stem Cells, Differentiations and
Cancer, Vancouver, Canada, Session Chair
Banbury Meeting on Curing Melanoma, Cold Spring Harbor
Laboratory, NY, Session Chair
AACR Annual Meeting, Orlando, FL
CSHL Symposium on Tumor Microenvironment, Cold Spring
Harbor, NY
Tetralogic, Malvern, PA
World Congress of Dermatology, Seoul, Korea
Engineered Tissue Models for Environmental Health Science Research,
NIEHS, Research Triangle Park, Chapel Hill, NC
4
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
2012
July 10
Nov. 29
Dec. 8
Dec. 16
European Post-ASCO Meeting, Munich, Germany
National Cancer Institute, Bethesda, MD
L’Oreal Inc., Paris, France
Expert Forum on Malignant Melanoma, Los Angeles, CA
Jan. 19
Feb. 2
Feb. 21
April 1
Virginia Commonwealth University, Richmond, VA
Dartmouth School of Medicine, Dartmouth, NH
German Cancer Congress, Berlin, Germany, Keynote Lecture
American Association for Cancer Research, Annual Meeting,
Major Symposium Speaker
AACR Special Conference on Resistance Mechanisms to
Targeted Therapy, San Diego, CA
Melanoma Research Foundation Breakthrough Consortium,
Chicago, IL
Genentech, San Francisco, CA
GenoMEL Annual Symposium, Leiden, Netherlands
Pigment Cell and Melanoma Research Symposium, NCI,
Bethesda, MD
SPORE in Skin Cancer, Yale University, New Haven, CT
University of Cologne, Cologne, Germany
L’Oreal Inc., Paris, France
May 10
June
June 12
June 18
June 22
July 27
August 13
Sept. 5
2013
Jan. 25
March 22
May 2
May 8
Sept. 5
Sept. 10
Sept. 17
Sept. 27
Nov. 20
Sandford-Burnham Institute, La Jolla, CA
German Cancer Society, Heidelberg, Germany
Hershey Medical Center, Hershey, PA, Award Lecture
International Melanoma Congress, Dublin, Ireland
Brazilian Workshop on Melanoma, São Paulo, Brazil, Keynote
Lecture
European Organization of Pigment Cell Research, Lisbon,
Portugal, Keynote Lecture
L’Oreal Inc., Paris, France
Temple University, Philadelphia, PA
SMR 10th International Congress, Philadelphia, PA
ADVISORY ROLES (past 5 years):
2008-2011
MRF, Board of Managers, Member
2009
Jan., Southwestern Melanoma SPORE, Denver, CO, External
Advisor
Jan., PO1 Biotherapy of Metastatic Melanoma: Biology and
Systemic Delivery of MDA7/IL-24, (E. Grimm, PI), MD
Anderson Cancer Center, Houston, TX, External Advisor
Feb., Oct., NCI Study Sections, Tumor Microenvironment (TME),
Ad Hoc
May, NCI Intramural Review, Laboratory of Cancer Prevention
July, NCI, Stage II Challenge Grant Review Committee, Ad Hoc
Oct., Utah Skin SPORE, External Advisor
Feb.-Dec., Grant Reviews for Funding Agencies in Netherlands,
Austria, Australia, Germany, Israel, Great Britain
5
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
2010
Joanna M. Nikolay Melanoma Foundation, Advisory Board
NDRI, Board of Directors, Chair
NCI, Feb., Oct., TME Study Section, Member
NCI, Special Emphasis Panel, Chair
MRA, Grant Review Committee, Co-Chair
Roche, Washington, DC, Advisor
Moffitt Cancer Center, Tampa, FL, SPORE Advisor
MRF Breakthrough Consortium, Board of Directors
MRF Breakthrough Consortium, Secretary Treasurer
2011
Melanoma Research Alliance, Scientific Review Committee CoChair
June, Tumor Microenvironment Network Study Section, NCI,
Chair
Sept., SPORE Study Section, Ad Hoc
Oct., TME NCI Study Section, Member
Jan.-Dec., Grant reviews from Austria, Germany, New Zealand,
Israel, Ireland, Netherlands, Norway
Grant Reviews for the Melanoma Research Foundation, Joanna
Nicolay Melanoma Foundation
NDRI, Board of Directors, Chair
MRF Breakthrough Consortium, Board of Directors
2013
Feb., Melanoma Research Alliance, Scientific Review
Committee, Member
May, NCI, Special Emphasis Panel, Ad Hoc Reviewer
June, Melanoma Research Alliance, Reviewer
August, Melanoma Research Foundation
NDRI, Board of Directors, Chair
MD Anderson, Skin SPORE
MRF Breakthrough Consortium, Board of Directors
SMR Congress 2013, Co-Organizer
Program Project, MD Anderson, L. Chin
FUNDING
Targeted Therapies in Melanoma
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: PO1 (CA114046-03)
Years 5-10, Period: May 16, 2008 to Oct. 1, 2018
Subproject 1: Senescence as an endpoint in melanoma therapy
Human Melanoma: Etiology, Progression, and Therapy
Principal Investigator: Meenhard Herlyn
Agency: NIH/NCI
Type: P01-Program Project (CA25874),
Years 30-34, Period: May 1, 2011 to April 30, 2016
Subproject on grant: Cellular mechanisms of therapy resistance
6
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
Biology of Melanoma Metastasis
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA47159)
Years 21-25, 2011-2016
Cell-Cell Communication During Melanoma Progression
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA76674)
Years 15-19, Period: April 1, 2011 to March 31, 2016
Mechanisms of Esophageal Carcinogenesis
Principal Investigator: Anil Rustgi; Co-Principal Investigator: Meenhard Herlyn
Agency: NIH/NCI
Type: P01-CA098101
Years 6-10, Period: July 1, 2009 – June 30, 2014
Subproject on grant: The tumor microenvironment in human esophageal squamous cell
carcinoma
The Role of Genetic Susceptibility in Melanoma Development
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA182890)
Years 1-5, Period: Dec. 1, 2013 to Nov. 30, 2018
CORE ACTIVITIES
1. Administrative Core A for Human Melanoma – Etiology, Progression & Therapy
(CA025874)
2. Administrative Core A for Targeted Therapies in Melanoma (CA114046)
3. Cell Biology Core C for Targeted Therapies in Melanoma (CA114046)
2013: Sponsored Agreements With industry (GSK, Novartis, Plexxikon, Tetralogic)
2013: Funding from Miriam and Sheldon Adelson Foundation for Medical Research,
Melanoma Research Alliance (Team Award), Melanoma Research Foundation
BIBLIOGRAPHY
Research Publications, Peer Reviewed
1. Buschmann H, Herlyn M. Stimulation of phagocytic activity by dextran. Z
Immunitatsforsch Exp Klin Immunol. 1972;143:209-210. PMID4282799
2. Mayr A, Streitferdt U, Herlyn M, Jaeger O. Vaccination of dogs against rabies. Die
Kleintierpraxis. 1973;18:91-96.
3. Danner K, Herlyn M, Gerbermann H, Mayr A. Oral immunization against pox. 5:
effectiveness of drinking water vaccination against fowl pox. Zentralbl Veterinärmed B.
1975;22:274-284. PMID169653
4. Mahnel H, Herlyn M. Stability of Teschen, HCC, ND and vaccinia viruses against 5
disinfectants. Zentralbl Veterinärmed B. 1976;23:403-411. PMID183417
7
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
Mahnel H, Ottis K, Herlyn M. Stability in drinking and surface water of nine virus species
from different genera (author’s transl). Zentralbl Bakteriol [Orig B]. 1977;164:64-84.
PMID14460
Danner K, Luthgen K, Herlyn M, Mayr A. Comparative studies on the demonstration and
formation of serum antibodies against the Borna virus. Zentralbl Veterinärmed B.
1978;25:345-355. PMID358683
Koprowski H, Steplewski Z, Herlyn D, Herlyn M. Study of antibodies against human
melanoma produced by somatic cell hybrids. Proc Natl Acad Sci U S A. 1978;75:34053409. PMID80012 (PMC392785)
Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal antibodies in cell-mediated
cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol.
1979;9:657-659. PMID499332
Herlyn M, Steplewski Z, Herlyn D, Koprowski H. Colorectal carcinoma-specific antigen:
detection by means of monoclonal antibodies. Proc Natl Acad Sci U S A. 1979;76:14381442. PMID286328 (PMC383267)
Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal
carcinoma antigens detected by Hybridoma. antibodies. Somatic Cell Genet. 1979;5:957971. PMID94699
Steplewski Z, Herlyn M, Herlyn D, Clark WH, Koprowski H. Reactivity of monoclonal antimelanoma antibodies with melanoma cells freshly isolated from primary and metastatic
melanoma. Eur J Immunol. 1979;9:94-96. PMID374094
Herlyn M, Clark WH Jr, Mastrangelo MJ, Guerry DT, Elder DE, LaRossa D, Hamilton R,
Bondi E, Tuthill R, Steplewski Z, Koprowski H. Specific immunoreactivity of hybridomasecreted monoclonal anti-melanoma antibodies to cultured cells and freshly derived
human cells. Cancer Res. 1980;40:3602-3609. PMID6159966
Herlyn DM, Steplewski Z, Herlyn MF, Koprowski H. Inhibition of growth of colorectal
carcinoma in nude mice by monoclonal antibody. Cancer Res. 1980;40:717-721.
PMID7471090
Wittek R, Herlyn M, Schumperli D, Bachmann PA, Mayr A, Wyler R. Genetic and
antigenic heterogeneity of different parapoxvirus strains. Intervirology. 1980;13:33-41.
PMID6153643
Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients
with colon carcinoma. Science. 1981;212:53-55. PMID6163212
Mayr A, Herlyn M, Mahnel H, Danco A, Zach A, Bostedt H. Control of ecthyma
contagiosum (pustular dermatitis) of sheep with a new parenteral cell culture live vaccine.
Zentralbl Veterinarmed B. 1981;28:535-552. PMID7331595
Sears HF, Herlyn D, Herlyn M, Grotzinger PJ, Steplewski Z, Gerhard W, Koprowski H. Ex
vivo perfusion of a tumor-containing colon with monoclonal antibody. J Surg Res.
1981;31:145-150. PMID6790874
Steplewski Z, Chang TH, Herlyn M, Koprowski H. Release of monoclonal antibodydefined antigens by human colorectal carcinoma and melanoma cells. Cancer Res.
1981;41:2723-2727. PMID7248940
Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal
cancer-associated antigen in immunoperoxidase assay. Cancer Res. 1982;42:4820-4823.
PMID6751528
Brockhaus M, Magnani JL, Herlyn M, Blaszczyk M, Steplewski Z, Koprowski H, Ginsburg
V. Monoclonal antibodies directed against the sugar sequence of lacto-N-fucopentaose III
are obtained from mice immunized with human tumors. Arch Biochem Biophys.
1982;217:647-651. PMID7138030
8
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
21. Herlyn M, Sears HF, Steplewski Z, Koprowski H. Monoclonal antibody detection of a
circulating tumor-associated antigen. I. Presence of antigen in sera of patients with
colorectal, gastric, and pancreatic carcinoma. J Clin Immunol. 1982;2:135-140.
PMID7068815
22. Herlyn M, Steplewski Z, Atkinson BF, Ernst CS, Koprowski H. Comparative study of the
binding characteristics of monoclonal antimelanoma antibodies. Hybridoma. 1982;1:403411. PMID6765323
23. Sears HF, Herlyn M, Del Villano B, Steplewski Z, Koprowski H. Monoclonal antibody
detection of a circulating tumor-associated antigen. II. A longitudinal evaluation of patients
with colorectal cancer. J Clin Immunol. 1982;2:141-149. PMID7068816
24. Sears HF, Herlyn D, Herlyn M, Steplewski Z, Grotzinger P, Koprowski H. Ex vivo
perfusion of human colon with monoclonal anticolorectal cancer antibodies. Cancer.
1982;49:1231-1235. PMID7059945
25. Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Use of
monoclonal antibodies in detection of melanoma-associated antigens in intact human
tumors. Am J Pathol. 107:357-361. PMID6177248 (PMC1916245)
26. Thompson JJ, Herlyn MF, Elder DE, Clark WH, Steplewski Z, Koprowski H. Expression of
DR antigens in freshly frozen human tumors. Hybridoma. 1982;1:161-168. PMID6208123
27. Folberg R, Donoso LA, Herlyn MF, Koprowski H. Antigens in ocular and cutaneous
melanomas. Am J Ophthalmol. 1983;96:394-395. PMID6351625
28. Hansson GC, Karlsson KA, Larson G, McKibbin JM, Blaszczyk M, Herlyn M, Steplewski
Z, Koprowski H. Mouse monoclonal antibodies against human cancer cell lines with
specificities for blood group and related antigens; characterization by antibody binding to
glycosphingolipids in a chromatogram binding assay. J Biol Chem. 1983;258:4091-4097.
PMID6833243
29. Herlyn M, Herlyn D, Elder DE, Bondi E, LaRossa D, Hamilton R, Sears HF, Balaban G,
Guerry D, Clark WH, Kaprowski H. Phenotypic characteristics of cells derived from
precursors of human melanoma. Cancer Res. 1983;43:5502-5508. PMID6616481
30. Herlyn D, Powe J, Alavi A, Mattis JA, Herlyn M, Ernst CS, Vaum R, Koprowski H.
Radioimmunodetection of human tumor xenografts by monoclonal antibodies. Cancer
Res. 1983;43:2731-2735. PMID6342757
31. Herlyn M, Steplewski Z, Herlyn D, Clark WH Jr, Ross AH, Blaszczyk M, Pak KY,
Koprowski H. Production and characterization of monoclonal antibodies against human
malignant melanoma. Cancer Invest. 1983;1:215-224. PMID6667406
32. Herlyn M, Blaszczyk M, Sears HF, Verrill H, Lindgren J, Colcher D, Steplewski Z, Schlom
J, Koprowski H. Detection of carcinoembryonic antigen and related antigens in sera of
patients with gastrointestinal tumors using monoclonal antibodies in double-determinant
radioimmunoassays. Hybridoma. 1983;2:329-339. PMID6205981
33. Mach JP, Chatal JF, Lumbroso JD, Buchegger F, Forni M, Ritschard J, Berche C,
Douillard JY, Carrel S, Herlyn M, Stepiewski Z, Koprowski H. Tumor localization in
patients by radiolabeled monoclonal antibodies against colon carcinoma. Cancer Res.
1983;43:5593-5600. PMID6616486
34. Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z, Koprowski H. Isolation and chemical
characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys.
1983;225:370-383. PMID6614928
35. Steplewski Z, Herlyn M, Blaszczyk M, Koprowski H. A simple procedure for determining
Lewis phenotypes in human saliva. J Immunol Methods. 1983;62:73-78. PMID6348171
36. Zehngebot LM, Alexander MA, Guerry DT, Cines DB, Mitchell K, Herlyn M. Functional
consequence of variation in melanoma antigen expression. Cancer Immunol Immunother.
1983;16:30-34. PMID6605801
9
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
37. Atkinson B, Ernst CS, Ghrist BF, Herlyn M, Blaszczyk M, Ross AH, Herlyn D, Steplewski
Z, Koprowski H. Identification of melanoma-associated antigens using fixed tissue
screening of antibodies. Cancer Res. 1984:44:2577-2581. PMID6722794
38. Balaban G, Herlyn M, Guerry DT, Bartolo R, Koprowski H, Clark WH, Nowell PC.
Cytogenetics of human malignant melanoma and premalignant lesions. Cancer Genet
Cytogenet. 1984;11:429-439. PMID6584203
39. Blaszczyk M, Hansson GC, Karlsson KA, Larson G, Stromberg N, Thurin J, Herlyn M,
Steplewski Z, Koprowski H. Lewis blood group antigens defined by monoclonal anti-colon
carcinoma antibodies. Arch Biochem Biophys. 1984;233:161-168. PMID6465894
40. Blaszczyk M, Pak KY, Herlyn M, Lindgren J, Pessano S, Steplewski Z, Koprowski H.
Characterization of gastrointestinal tumor-associated carcinoembryonic antigen-related
antigens defined by monoclonal antibodies. Cancer Res. 1984;44:245-253.
PMID6360346
41. Donoso LA, Folberg R, Angiolillo P, Herlyn M. A 19-9 monoclonal antibody study of
adenocarcinoma metastatic to the choroid. Am J Ophthalmol. 1984;98:815-816.
PMID6507563
42. Ernst CS, Thurin J, Atkinson B, Wurzel H, Herlyn M, Stromberg N, Civin C, Koprowski H.
Monoclonal antibody localization of A and B isoantigens in normal and malignant fixed
human tissues. Am J Pathol. 1984;117:451-461. PMID6507589
43. Ernst CS, Atkinson B, Wysocka M, Blaszczyk M, Herlyn M, Sears H, Steplewski Z,
Koprowski H. Monoclonal antibody localization of Lewis antigens in fixed tissue. Lab
Invest. 1984;50:394-400. PMID6368970 (PMC1900579)
44. Guerry DT, Alexander MA, Herlyn MF, Zehngebot LM, Mitchell KF, Zmijewski CM, Lusk
EJ. HLA-DR histocompatibility leukocyte antigens permit cultured human melanoma cells
from early but not advanced disease to stimulate autologous lymphocytes. J Clin Invest.
1984;73:267-271. PMID6606651
45. Herlyn M, Sears HF, Verrill H, Koprowski H. Increased sensitivity in detecting tumorassociated antigens in sera of patients with colorectal carcinoma. J Immunol Methods.
1984;75:15-21. PMID6512262
46. Herlyn D, Herlyn M, Ross AH, Ernst CS, Atkinson B, Koprowski H. Efficient selection of
human tumor growth-inhibiting monoclonal antibodies. J Immunol Methods. 1984;73:157167. PMID6491298
47. Herlyn M, Lange B, Bennicelli J, Blaszczyk M, Guerry DT, Koprowski H. Increased levels
of circulating HLA-DR antigen in sera of patients with acute lymphoblastoid leukemia.
Leuk Res. 1984;8:323-334. PMID6431198
48. Herlyn M, Shen JW, Sears HF, Civin CI, Verrill HL, Goldberg EM, Koprowski H. Detection
of a circulating gastrointestinal cancer antigen in sera of patients with gastrointestinal
malignancies by a double determinant immunoassay with monoclonal antibodies against
human blood group determinants. Clin Exp Immunol. 1984;55:23-35. PMID6198117
(PMC1535790)
49. Miller SL, Pleasure D, Herlyn M, Atkinson B, Ernst CS, Tachovsky TG, Baird L.
Production and characterization of monoclonal antibodies to peripheral and central
nervous system myelin. J Neurochem. 1984;43:394-400. PMID6204014
50. Pak KY, Blaszczyk M, Herlyn M, Steplewski Z, Koprowski H. Identification and isolation of
Lewis blood group antigens from human saliva using monoclonal antibodies. Hybridoma.
1984;3:1-10. PMID6469267
51. Pegg AE, Seely JE, Persson L, Herlyn M, Ponsell K, O’Brien TG. Studies of mammalian
ornithine decarboxylase using a monoclonal antibody. Biochem J. 1984;217:123-128.
PMID6421279 (PMC1153189)
10
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
52. Ross AH, Grob P, Bothwell M, Elder DE, Ernst CS, Marano N, Ghrist BF, Slemp CC,
Herlyn M, Atkinson B, Koprowski H. Characterization of nerve growth factor receptor in
neural crest tumors using monoclonal antibodies. Proc Natl Acad Sci U S A.
1984;81:6681-6685. PMID6093111 (PMC391994)
53. Ross AH, Herlyn M, Ernst CS, Guerry D, Bennicelli J, Ghrist BF, Atkinson B, Koprowski
H. Immunoassay for melanoma-associated proteoglycan in the sera of patients using
monoclonal and polyclonal antibodies. Cancer Res. 1984;44:4642-4647. PMID6380710
54. Verrill H, Goldberg M, Kovac G, Atkinson B, Herlyn M. Evaluation of monoclonal antibody
to 19-9 antigen as a potential screening technique for colorectal cancer in a high-risk
population. Prog Clin Biol Res. 1984;156:107-114. PMID6382320
55. Atkinson B, Ernst CS, Ghrist BF, Ross AH, Clark WH, Herlyn M, Herlyn D, Maul G,
Steplewski Z, Koprowski H. Monoclonal antibody to a highly glycosylated protein reacts in
fixed tissue with melanoma and other tumors. Hybridoma. 1985;4:243-255. PMID4043988
56. Blaszczyk M, Pak KY, Herlyn M, Sears HF, Steplewski Z. Characterization of Lewis
antigens in normal colon and gastrointestinal adenocarcinomas. Proc Natl Acad Sci U S
A. 1985;82:3552-3556. PMID2582419 (PMC397823)
57. Donoso LA, Folberg R, Edelberg K, Arbizo V, Atkinson B, Herlyn M. Tissue distribution
and biochemical properties of an ocular melanoma-associated antigen. J Histochem
Cytochem. 1985;33:1190-1196. PMID3905953
58. Folberg R, Donoso LA, Atkinson BF, Ernst CS, Herlyn M, Arbizo VV. An antimelanoma
monoclonal antibody and the histopathology of uveal melanomas. Arch Ophthalmol.
1985;103:275-279. PMID2579631
59. Herlyn M, Thurin J, Balaban G, Bennicelli JL, Herlyn D, Elder DE, Bondi E, Guerry D,
Nowell P, Clark WH, Koprowski H. Characteristics of cultured human melanocytes
isolated from different stages of tumor progression. Cancer Res. 1985;45:5670-5676.
PMID4053039
60. Herlyn M, Blaszczyk M, Bennicelli J, Sears HF, Ernst CS, Ross AH, Koprowski H.
Selection of monoclonal antibodies detecting serodiagnostic human tumor markers. J
Immunol Methods. 1985;80:107-116. PMID3859550
61. Herlyn M, Guerry D, Koprowski H. Recombinant gamma-interferon induces changes in
expression and shedding of antigens associated with normal human melanocytes, nevus
cells, and primary and metastatic melanoma cells. J Immunol. 1985;134:4226-4230.
PMID2985706
62. Herlyn D, Herlyn M, Steplewski Z, Koprowski H. Monoclonal anti-human tumor antibodies
of six isotypes in cytotoxic reactions with human and murine effector cells. Cell Immunol.
1985;92:105-114. PMID4075410
63. Herlyn D, Powe J, Ross AH, Herlyn M, Koprowski H. Inhibition of human tumor growth by
IgG2A monoclonal antibodies correlates with antibody density on tumor cells. J Immunol.
1985;134:1300-1304. PMID3965572
64. Herlyn M, Balaban G, Bennicelli J, Guerry DT, Halaban R, Herlyn D, Elder DE, Maul GG,
Steplewski Z, Nowell PC. Primary melanoma cells of the vertical growth phase:
similarities to metastatic cells. J Natl Cancer Inst. 1985;74:283-289. PMID3856042
65. Koprowska I, Zipfel SA, Himes TR, Herlyn M. Common antigenic sites on exfoliated cells
derived from cervical carcinoma and in tumor cells of nonuterine origin as demonstrated
by monoclonal antibodies in immunoperoxidase assay. Cancer Res. 1985;45:5964-5968.
PMID2414003
66. Koprowski H, Herlyn M, Balaban G, Parmiter A, Ross A, Nowell P. Expression of the
receptor for epidermal growth factor correlates with increased dosage of chromosome 7
in malignant melanoma. Somat Cell Mol Genet. 1985;11:297-302. PMID2988138
11
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
67. Matera L, Francis MK, Herlyn M, Trucco M, Santoli D. Generation of natural killer-like
activity in mixed lymphocyte-tumor cell cultures. I. Role of HLA-DR antigens as
stimulatory molecules. Nat Immun Cell Growth Regul. 1985;4:90-102. PMID3160934
68. Sears HF, Shen JW, Herlyn M, Atkinson B, Engstrom PF, Koprowski H. Circulating tumor
markers and assessment of response to intrahepatic chemotherapy of colon carcinoma.
Am J CIin Oncol. 1985;8:108-117. PMID2929709
69. Thurin J, Herlyn M, Hindsgaul O, Stromberg N, Karlsson KA, Elder D, Steplewski Z,
Koprowski H. Proton NMR and fast-atom bombardment mass spectrometry analysis of
the melanoma-associated ganglioside 9-O-acetyl-GD3. J Biol Chem. 1985;260:1455614563. PMID4055789
70. Balaban GB, Herlyn M, Clark WH Jr, Nowell PC. Karyotypic evolution in human malignant
melanoma. Cancer Genet Cytogenet. 1986;19:113-122. PMID3940171
71. Donoso LA, Felberg NT, Edelberg K, Borlinghaus P, Herlyn M. Metastatic uveal
melanoma: an ocular melanoma associated antigen in the serum of patients with
metastatic disease. J Immunoassay. 1986;7:273-283. PMID3805289
72. Ernst CS, Shen JW, Litwin S, Herlyn M, Koprowski H, Sears HF. Multiparameter
evaluation of the expression in situ of normal and tumor-associated antigens in human
colorectal carcinoma. J Natl Cancer Inst. 1986;77:387-395. PMID3461200
73. Ernst CS, Sears HF, Herlyn M, Herlyn D, Steplewski Z, Koprowski H. Detection of murine
immunoglobulin in human tissues following therapeutic infusion of monoclonal antibody.
Hybridoma. 1986;5(suppl 1):S79-86. PMID3527948
74. Ernst CS, Atkinson B, Chianese D, Peters J, Perry M, Herlyn M, Koprowski H. Differential
diagnosis between mesotheliomas and metastatic adenocarcinomas using monoclonal
antibodies against gastrointestinal carcinoma antigen and stage-specific embryonic
antigen. Appl Pathol. 1986;4:115-124. PMID2885017
75. Herlyn D, Powe J, Munz DL, Alavi A, Herlyn M, Meinken GE, Srivastava SC, Koprowski
H. Radioimmunodetection of human tumor xenografts by monoclonal antibody F(ab’)2
fragments. Int J Rad Appl Instrum B. 1986;13:401-405. PMID3793494
76. Koprowska I, Zipfel S, Ross AH, Herlyn M. Development of monoclonal antibodies that
recognize antigens associated with human cervical carcinoma. Acta Cytol. 1986;30:207213. PMID3521172
77. Parmiter AH, Balaban G, Herlyn M, Clark WH Jr, Nowell PC. A t(1;19) chromosome
translocation in three cases of human malignant melanoma. Cancer Res. 1986;46:15261529. PMID3943110
78. Rakowicz-Szulczynska EM, Rodeck U, Herlyn M, Koprowski H. Chromatin binding of
epidermal growth factor, nerve growth factor, and platelet-derived growth factor in cells
bearing the appropriate surface receptors. Proc Natl Acad Sci U S A. 1986;83:3728-3732.
PMID3012531 (PMC323596)
79. Steplewski Z, Herlyn D, Lubeck M, Kimoto Y, Herlyn M, Koprowski H. Mechanisms of
tumor growth inhibition. Hybridoma. 1986;5(suppl 1):S59-64. PMID3744386
80. Thurin J, Thurin M, Herlyn M, Elder DE, Steplewski Z, Clark WH Jr, Koprowski H. GD2
ganglioside biosynthesis is a distinct biochemical event in human melanoma tumor
progression. FEBS Lett. 1986;208:17-22. PMID3533633
81. Westermark B, Johnsson A, Paulsson Y, Betsholtz C, Heldin CH, Herlyn M, Rodeck U,
Koprowski H. Human melanoma cell lines of primary and metastatic origin express the
genes encoding the chains of platelet-derived growth factor (PDGF) and produce a
PDGF-like growth factor. Proc Natl Acad Sci U S A.1986;83:7197-7200. PMID3020539
(PMC386682)
12
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
82. Basu A, Murthy U, Rodeck U, Herlyn M, Mattes L, Das M. Presence of tumor-associated
antigens in epidermal growth factor receptors from different human carcinomas. Cancer
Res. 1987;47:2531-2536. PMID2436750
83. Guerry DT, Herlyn MF, Elder DE, Herlyn MF. Interferon-gamma regulates the T cell
response to precursor nevi and biologically early melanoma. J Immunol. 1987;139:305312. PMID3108402
84. Herlyn M, Rodeck U, Mancianti M, Cardillo FM, Lang A, Ross AH, Jambrosic J,
Koprowski H. Expression of melanoma-associated antigens in rapidly dividing human
melanocytes in culture. Cancer Res. 1987;47:3057-3061. PMID3034401
85. Menssen HD, Herlyn M, Rodeck U, Koprowski H. Rapid dissociation of adherent human
tumor cells by ultrasound. J Immunol Methods. 1987;104:1-6. PMID3316390
86. Murthy U, Basu A, Rodeck U, Herlyn M, Ross AH, Das M. Binding of an antagonistic
monoclonal antibody to an intact and fragmented EGF-receptor polypeptide. Arch
Biochem Biophys. 1987;252:549-560. PMID2434025
87. Ordonez NG, Freedman RS, Herlyn M. Lewis and related tumor-associated determinants
on ovarian carcinoma. Gynecol Oncol. 1987;26:1-10. PMID2431961
88. Rodeck U, Herlyn M, Koprowski H. Interactions between growth factor receptors and
corresponding monoclonal antibodies in human tumors. J Cell Biochem. 1987;35:315320. PMID2831241
89. Rodeck U, Herlyn M, Menssen HD, Furlanetto RW, Koprowski H. Metastatic but not
primary melanoma cell lines grow in vitro independently of exogenous growth factors. Int
J Cancer. 1987;40:687-690. PMID3316051
90. Rodeck U, Herlyn M, Leander K, Borlinghaus P, Koprowski H. A mucin containing the X,
Y, and H type 2 carbohydrate determinants is shed by carcinoma cells. Hybridoma.
1987;6:389-401. PMID2442094
91. Rodeck U, Herlyn M, Herlyn D, Molthoff C, Atkinson B, Varello M, Steplewski Z,
Koprowski H. Tumor growth modulation by a monoclonal antibody to the epidermal
growth factor receptor: immunologically mediated and effector cell-independent effects.
Cancer Res. 1987;47:3692-3696. PMID3297307
92. Thurin J, Thurin M, Kimoto Y, Herlyn M, Lubeck MD, Elder DE, Smereczynska M,
Karlsson KA, Clark WM Jr, Steplewski Z, Koprowski H. Monoclonal antibody-defined
correlations in melanoma between levels of GD2 and GD3 antigens and antibodymediated cytotoxicity. Cancer Res. 1987;47:1229-1233. PMID3815333
93. Tsujisaki M, Igarashi M, Sakaguchi K, Eisinger M, Herlyn M, Ferrone S. Immunochemical
and functional analysis of HLA class II antigens induced by recombinant immune
interferon on normal epidermal melanocytes. J Immunol. 1987;138:1310-1316.
PMID3100635
94. Herlyn M, Mancianti ML, Jambrosic J, Bolen JB, Koprowski H. Regulatory factors that
determine growth and phenotype of normal human melanocytes. Exp Cell Res.
1988;179:322-331. PMID2461309
95. Linnenbach AJ, Huebner K, Reddy EP, Herlyn M, Parmiter AH, Nowell PC, Koprowski H.
Structural alteration in the MYB protooncogene and deletion within the gene encoding
alpha-type protein kinase C in human melanoma cell lines. Proc Natl Acad Sci U S A.
1988;85:74-78. PMID2829178 (PMC279484)
96. Mancianti ML, Herlyn M, Weil D, Jambrosic J, Rodeck U, Becker D, Diamond L, Clark
WH, Koprowski H. Growth and phenotypic characteristics of human nevus cells in culture.
J Invest Dermatol.1988;90:134-141, 1988. PMID2828480
97. Rakowicz-Szulczynska EM, Herlyn M, Koprowski H. Nerve growth factor receptors in
chromatin of melanoma cells, proliferating melanocytes, and colorectal carcinoma cells in
vitro. Cancer Res. 1988;48:7200-7206. PMID2461254
13
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
98. Williams NW, Rodeck U, Daly JM, Herlyn M. Growth regulatory factors for human
colorectal carcinoma cells in vitro. Surgical Forum. 1988;39:445-447.
99. Becker D, Meier CB, Herlyn M. Proliferation of human malignant melanomas is inhibited
by antisense oligodeoxynucleotides targeted against basic fibroblast growth factor. Embo
J. 1989;8:3685-3691. PMID2684645 (PMC402051)
100. Berd D, Herlyn M, Koprowski H, Mastrangelo MJ. Flow cytometric determination of the
frequency and heterogeneity of expression of human melanoma-associated antigens.
Cancer Res. 1989;49:6840-6844. PMID2582430
101. Elder DE, Rodeck U, Thurin J, Cardillo F, Clark WH, Stewart R, Herlyn M. Antigenic
profile of tumor progression stages in human melanocytic nevi and melanomas. Cancer
Res. 1989;49:5091-5096. PMID2548711
102. Iliopoulos D, Ernst CS, Steplewski Z, Jambrosic JA, Rodeck U, Herlyn M, Clark WH Jr,
Koprowski H, Herlyn D. Inhibition of metastases of a human melanoma xenograft by
monoclonal antibody to the GD2/GD3 gangliosides. J Natl Cancer Inst. 1989;81:440-444.
PMID2918552
103. Jambrosic J, Mancianti ML, Ricciardi R, Sela BA, Koprowski H, Herlyn M. Transformation
of normal human melanocytes and non-malignant nevus cells by adenovirus 12-SV40
hybrid virus. Int J Cancer. 1989;44:1117-1123. PMID2558080
104. Kraemer KH, Herlyn M, Yuspa SH, Clark WH Jr, Townsend GK, Neises GR, Hearing VJ.
Reduced DNA repair in cultured melanocytes and nevus cells from a patient with
xeroderma pigmentosum. Arch Dermatol. 125:263-268, 1989. PMID2913963
105. Strom BL, Iliopoulos D, Atkinson B, Herlyn M, West SL, Maislin G, Saul S, Varello MA,
Rodriguez-Martinez HA, Rios-Dalenz J. Pathophysiology of tumor progression in human
gallbladder: flow cytometry, CEA, and CA 19-9 levels in bile and serum in different stages
of gallbladder disease. J Natl Cancer Inst. 1989;81:1575-1580. PMID2795683
106. Wolf BC, Salem RR, Sears HF, Horst DA, Lavin PT, Herlyn M, Itzkowitz SH, Schlom J,
Steele GD Jr. The expression of colorectal carcinoma-associated antigens in the normal
colonic mucosa. An immunohistochemical analysis of regional distribution. Am J Pathol.
1989;135:111-119. PMID2476033 (PMC1880239)
107. Albelda SM, Mette SA, Elder DE, Stewart R, Damjanovich L, Herlyn M, Buck CA. Integrin
distribution in malignant melanoma: association of the beta 3 subunit with tumor
progression. Cancer Res. 1990;50:6757-6764. PMID2208139
108. Becker D, Beebe SJ, Herlyn M. Differential expression of protein kinase C and cAMPdependent protein kinase in normal human melanocytes and malignant melanomas.
Oncogene. 1990;5:1133-1139. PMID2392322
109. Dion AS, Williams CJ, Herlyn M, Major P. Human milk fat globule membrane
glycoproteins express blood group-related determinants primarily on mucin-like epithelial
membrane antigens and gp70. Biochem Int. 1990;22:295-302. PMID1708665
110. Howe CC, Kath R, Mancianti ML, Herlyn M, Mueller S, Cristofalo V. Expression and
structure of human SPARC transcripts: SPARC mRNA is expressed by human cells
involved in extracellular matrix production and some of these cells show an unusual
expression pattern. Exp Cell Res. 1990;188:185-191. PMID2335186
111. Kath R, Rodeck U, Parmiter A, Jambrosic J, Herlyn M. Growth factor independence in
vitro of primary melanoma cells from advanced but not early or intermediate lesions.
Cancer Therapy and Control. 1990;1:179-191.
112. Mancianti ML, Clark WH, Hayes FA, Herlyn M. Malignant melanoma simulants arising in
congenital melanocytic nevi do not show experimental evidence for a malignant
phenotype. Am J Pathol.1990;136:817-829. PMID2327470 (PMC1877645)
113. Manni A, Wright C, Badger B, Bartholomew M, Herlyn M, Mendelsohn J, Masui H,
Demers L. Role of transforming growth factor-alpha-related peptides in the
14
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
autocrine/paracrine control of experimental breast cancer growth in vitro by estradiol,
prolactin, and progesterone. Breast Cancer Res Treat. 1990;15:73-83. PMID2322651
114. Rodeck U, Williams N, Murthy U, Herlyn M. Monoclonal antibody 425 inhibits growth
stimulation of carcinoma cells by exogenous EGF and tumor-derived EGF/TGF-alpha. J
Cell Biochem. 1990;44:69-79. PMID2250044
115. Singletary SE, Williams NN, Rodeck U, Larry L, Tucker S, Spitzer G, Herlyn M.
Transforming growth factor-alpha secretion by epidermal growth factor-dependent human
tumor cell lines. Anticancer Res. 1990;10:1501-1505. PMID2285223
116. Strom BL, Maislin G, West SL, Atkinson B, Herlyn M, Saul S, Rodriguez-Martinez HA,
Rios-Dalenz J, Iliopoulos D, Soloway RD. Serum CEA and CA 19-9: potential future
diagnostic or screening tests for gallbladder cancer? Int J Cancer. 1990;45:821-824.
PMID2335386
117. Valyi-Nagy IT, Murphy GF, Mancianti ML, Whitaker D, Herlyn M. Phenotypes and
interactions of human melanocytes and keratinocytes in an epidermal reconstruction
model. Lab Invest. 1990;62:314-324. PMID2179623
118. Bröcker EB, Magiera H, Herlyn M. Nerve growth and expression of receptors for nerve
growth factor in tumors of melanocyte origin. J Invest Dermatol.1991;96:662-665.
PMID1850772
119. Cornil I, Theodorescu D, Man S, Herlyn M, Jambrosic J, Kerbel RS. Fibroblast cell
interactions with human melanoma cells affect tumor cell growth as a function of tumor
progression. Proc Natl Acad Sci U S A. 1991;88:6028-6032. PMID2068080 (PMC52015)
120. Herlyn M, Graeven U, Speicher D, Sela BA, Bennicelli JL, Kath R, Guerry DT.
Characterization of tenascin secreted by human melanoma cells. Cancer Res.
1991;51:4853-4858. PMID1716515
121. Kath R, Jambrosic JA, Holland L, Rodeck U, Herlyn M. Development of invasive and
growth factor-independent cell variants from primary human melanomas. Cancer Res.
1991;51:2205-2211. PMID2009539
122. Radrizzani M, Benedetti B, Castelli C, Longo A, Ferrara GB, Herlyn M, Parmiani G,
Fossati G. Human allogeneic melanoma-reactive T-helper lymphocyte clones: functional
analysis of lymphocyte-melanoma interactions. Int J Cancer. 1991;49:823-830.
PMID1835714
123. Rodeck U, Melber K, Kath R, Menssen HD, Varello M, Atkinson B, Herlyn M. Constitutive
expression of multiple growth factor genes by melanoma cells but not normal
melanocytes. J Invest Dermatol. 1991;97:20-26. PMID2056188
124. Becker D, Lee PL, Rodeck U, Herlyn M. Inhibition of the fibroblast growth factor receptor
1 (FGFR-1) gene in human melanocytes and malignant melanomas leads to inhibition of
proliferation and signs indicative of differentiation. Oncogene. 1992;7:2303-2313.
PMID1437152
125. Ura Y, Dion AS, Williams CJ, Olsen BD, Redfield ES, Ishida M, Herlyn M, Major PP.
Quantitative dot blot analyses of blood-group-related antigens in paired normal and
malignant human breast tissues. Int J Cancer. 1992;50:57-63. PMID1728614
126. Williams NN, Györfi T, Iliopoulos D, Herlyn D, Greenstein D, Linnenbach AJ, Daly JM,
Jensen P, Rodeck U, Herlyn M. Growth-factor-independence and invasive properties of
colorectal carcinoma cells. Int J Cancer. 1992;50:274-280. PMID1730521
127. Anichini A, Maccalli C, Mortarini R, Salvi S, Mazzocchi A, Squarcina P, Herlyn M,
Parmiani G. Melanoma cells and normal melanocytes share antigens recognized by HLAA2-restricted cytotoxic T cell clones from melanoma patients. J Exp Med. 1993;177:989998. PMID8459226
15
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
128. Easty DJ, Ganz SE, Farr CJ, Lai C, Herlyn M, Bennett DC. Novel and known protein
tyrosine kinases and their abnormal expression in human melanoma. J Invest Dermatol.
1993;101:679-684. PMID8228328
129. Forsberg K, Valyi-Nagy I, Heldin CH, Herlyn M, Westermark B. Platelet-derived growth
factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in
xenotransplanted human melanoma producing PDGF-BB. Proc Natl Acad Sci U S A.
1993;90:393-397. PMID8380638 (PMC45668)
130. Iliopoulos D, Atkinson B, Saul SH, Herlyn M, Rodriguez-Martinez HA, West SL, Maislin G,
Soloway RD, Strom BL. Differences in antigen expression between neoplastic and
nonneoplastic gallbladder epithelium: an immunohistochemical study. Dig Dis Sci.
1993;38:155-160. PMID8420749
131. Juhasz I, Lazarus GS, Murphy GF, Shih IM, Herlyn M. Development of pemphigus
vulgaris-like lesions in severe combined immunodeficiency disease mice reconstituted
with lymphocytes from patients. J Clin Invest. 1993;92:2401-2407. PMID8227357
(PMC288423)
132. Juhasz I, Murphy GF, Yan HC, Herlyn M, Albelda SM. Regulation of extracellular matrix
proteins and integrin cell substratum adhesion receptors on epithelium during cutaneous
human wound healing in vivo. Am J Pathol. 1993;143:1458-1469. PMID7694470
(PMC1887182)
133. Juhasz I, Albelda SM, Elder DE, Murphy GF, Adachi K, Herlyn D, Valyi-Nagy IT, Herlyn
M. Growth and invasion of human melanomas in human skin grafted to immunodeficient
mice. Am J Pathol. 1993;143:528-537. PMID8342600 (PMC1887031)
134. Lazzaro B, Elder DE, Rebers A, Power L, Herlyn M, Menrad A, Johnson B.
Immunophenotyping of compound and spitz nevi and vertical growth-phase melanomas
using a panel of monoclonal antibodies reactive in paraffin sections. J Invest
Dermatol.1993;100:313S-317S. PMID8440911
135. Mancianti ML, Györfi T, Shih IM, Valyi-Nagy I, Levengood G, Menssen HD, Halpern AC,
Elder DE, Herlyn M. Growth regulation of cultured human nevus cells. J Invest Dermatol.
1993;100:281S-287S. PMID8440904
136. Menrad A, Speicher D, Wacker J, Herlyn M. Biochemical and functional characterization
of aminopeptidase N expressed by human melanoma cells. Cancer Res. 1993;53:14501455. PMID8095183
137. Salem RR, Wolf BC, Sears HF, Lavin PT, Ravikumar TS, DeCoste D, D’Emilia JC, Herlyn
M, Schlom J, Gottlieb LS, Steele DG. Expression of colorectal carcinoma-associated
antigens in colonic polyps. J Surg Res. 1993;55:249-255. PMID8412106
138. Sensi M, Salvi S, Castelli C, Maccalli C, Mazzocchi A, Mortarini R, Nicolini G, Herlyn M,
Parmiani G, Anichini A. T cell receptor (TCR) structure of autologous melanoma-reactive
cytotoxic T lymphocyte (CTL) clones: tumor-infiltrating lymphocytes overexpress in vivo
the TCR beta chain sequence used by an HLA-A2-restricted and melanocyte-lineagespecific CTL clone. J Exp Med. 1993;178:1231-1246. PMID8376931
139. Valyi-Nagy IT, Hirka G, Jensen PJ, Shih IM, Juhasz I, Herlyn M. Undifferentiated
keratinocytes control growth, morphology, and antigen expression of normal melanocytes
through cell-cell contact. Lab Invest. 1993;69:152-159. PMID8350597
140. Valyi-Nagy I, Shih IM, Györfi T, Greenstein D, Juhasz I, Elder DE, Herlyn M. Spontaneous
and induced differentiation of human melanoma cells. Int J Cancer. 1993;54:159-165.
PMID8478142
141. Weiss J, Schwechheimer K, Cavenee WK, Herlyn M, Arden KC. Mutation and expression
of the p53 gene in malignant melanoma cell lines. Int J Cancer. 1993;54:693-699.
PMID8514460
16
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
142. Yan HC, Juhasz I, Pilewski J, Murphy GF, Herlyn M, Albelda SM. Human/severe
combined immunodeficient mouse chimeras: an experimental in vivo model system to
study the regulation of human endothelial cell-leukocyte adhesion molecules. J Clin
Invest. 1993;91:986-996. PMID7680673 (PMC288051)
143. Gratas C, Herlyn M, Becker D. Isolation and analysis of novel human melanocyte-specific
cDNA clones. DNA Cell Biol. 1994;13:515-519. PMID8024694
144. Hijiya N, Zhang J, Ratajczak MZ, Kant JA, DeRiel K, Herlyn M, Zon G, Gewirtz AM.
Biologic and therapeutic significance of MYB expression in human melanoma. Proc Natl
Acad Sci U S A. 1994;91:4499-4503. PMID8183937 (PMC43813)
145. Marincola FM, Shamamian P, Alexander RB, Gnarra JR, Turetskaya RL, Nedospasov
SA, Simonis TB, Taubenberger JK, Yannelli J, Mixon A, Restifo NP, Herlyn M, Rosenberg
SA. Loss of HLA haplotype and B locus down-regulation in melanoma cell lines. J
Immunol. 1994;153:1225-1237. PMID8027550
146. Mattei S, Colombo MP, Melani C, Silvani A, Parmiani G, Herlyn M. Expression of
cytokine/growth factors and their receptors in human melanoma and melanocytes. Int J
Cancer. 1994;56:853-857. PMID7509778
147. Quong RY, Bickford ST, Ing YL, Terman B, Herlyn M, Lassam NJ. Protein kinases in
normal and transformed melanocytes. Melanoma Res. 1994;4:313-319. PMID7858416
148. Shih IM, Elder DE, Hsu M-Y, Herlyn M. Regulation of Mel-CAM/MUC18 expression on
melanocytes of different stages of tumor progression by normal keratinocytes. Am J
Pathol. 1994;145:837-845. PMID7943174 (PMC1887332)
149. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M. Isolation and functional
characterization of the A32 melanoma-associated antigen. Cancer Res. 1994;54:25142520. PMID8162602
150. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, Treisman J, Rosenberg
SA. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent
5-aza-2’-deoxycytidine. Cancer Res. 1994;54:1766-1771. PMID7511051
151. Easty DJ, Guthrie BA, Maung K, Farr CJ, Lindberg RA, Toso RJ, Herlyn M, Bennett DC.
Protein B61 as a new growth factor: expression of B61 and up-regulation of its receptor
epithelial cell kinase during melanoma progression. Cancer Res. 1995;55:2528-2532.
PMID7780963
152. Easty DJ, Herlyn M, Bennett DC. Abnormal protein tyrosine kinase gene expression
during melanoma progression and metastasis. Int J Cancer. 1995;60:129-136.
PMID7814145
153. Jiang H, Lin J, Su ZZ, Herlyn M, Kerbel RS, Weissman BE, Welch DR, Fisher PB. The
melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent
kinase inhibitor p21, is differentially expressed during growth, differentiation and
progression in human melanoma cells. Oncogene. 1995;10:1855-1864. PMID7753561
154. Mortarini R, Gismondi A, Maggioni A, Santoni A, Herlyn M, Anichini A. Mitogenic activity
of laminin on human melanoma and melanocytes: different signal requirements and role
of beta 1 integrins. Cancer Res. 1995;55:4702-4710. PMID7553652
155. Soballe PW, Maloy WL, Myrga ML, Jacob LS, Herlyn M. Experimental local therapy of
human melanoma with lytic magainin peptides. Int J Cancer. 1995;60:280-284.
PMID7829229
156. Hsu M-Y, Wheelock MJ, Johnson KR, Herlyn M. Shifts in cadherin profiles between
human normal melanocytes and melanomas. J Investig Dermatol Symp Proc.
1996;1:188-194. PMID9627715
157. Juhasz I, Simon M Jr, Herlyn M, Hunyadi J. Repopulation of Langerhans cells during
wound healing in an experimental human skin/SCID mouse model. Immunol Lett.
1996;52:125-128. PMID8905406
17
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
158. Marincola FM, Hijazi YM, Fetsch P, Salgaller ML, Rivoltini L, Cormier J, Simonis TB,
Duray PH, Herlyn M, Kawakami Y, Rosenberg SA. Analysis of expression of the
melanoma-associated antigens MART-1 and gp100 in metastatic melanoma cell lines and
in in situ lesions. J Immunother Emphasis Tumor Immunol. 1996;19:192-205.
PMID8811494
159. Simon M Jr, Juhasz I, Herlyn M, Hunyadi J. Thrombospondin receptor (CD36) expression
of human keratinocytes during wound healing in a SCID mouse/human skin repair model.
J Dermatol. 1996;23:305-309. PMID9675818
160. Soballe PW, Montone KT, Satyamoorthy K, Nesbit M, Herlyn M. Carcinogenesis in
human skin grafted to SCID mice. Cancer Res. 1996;56:757-764. PMID8631010
161. Andalib AR, Lawry J, Ali SA, Murray AK, Sisley K, Silcocks P, Herlyn M, Rees RC.
Cytokine modulation of antigen expression in human melanoma cell lines derived from
primary and metastatic tumour tissues. Melanoma Res. 1997;7:32-42. PMID9067963
162. Atillasoy ES, Elenitsas R, Sauter ER, Soballe PW, Herlyn M. UVB induction of epithelial
tumors in human skin using a RAG-1 mouse xenograft model. J Invest
Dermatol.1997;109:704-709. PMID9406808
163. Satyamoorthy K, DeJesus E, Linnenbach AJ, Kraj B, Kornreich DL, Rendle S, Elder DE,
Herlyn M. Melanoma cell lines from different stages of progression and their biological
and molecular analyses. Melanoma Res. 1997;7(suppl 2):S35-42. PMID9578514
164. Satyamoorthy K, Soballe PW, Soans F, Herlyn M. Adenovirus infection enhances killing
of melanoma cells by a mitotoxin. Cancer Res. 1997;57:1873-1876. PMID9157978
165. Shih IM, Speicher D, Hsu M-Y, Levine E, Herlyn M. Melanoma cell-cell interactions are
mediated through heterophilic Mel-CAM/ligand adhesion. Cancer Res. 1997;57:38353840. PMID9288796 (PMC1857834)
166. Shih IM, Hsu M-Y, Palazzo JP, Herlyn M. The cell-cell adhesion receptor Mel-CAM acts
as a tumor suppressor in breast carcinoma. Am J Pathol. 1997;151:745-751.
PMID9284823
167. Wechsler-Reya R, Elliott K, Herlyn M, Prendergast GC. The putative tumor suppressor
BIN1 is a short-lived nuclear phosphoprotein, the localization of which is altered in
malignant cells. Cancer Res. 1997;57:3258-3263. PMID9242458
168. Atillasoy ES, Seykora JT, Soballe PW, Elenitsas R, Nesbit M, Elder DE, Montone KT,
Sauter E, Herlyn M. UVB induces atypical melanocytic lesions and melanoma in human
skin. Am J Pathol. 1998;152:1179-1186. PMID9588887 (PMC1858575)
169. Cass DL, Bullard KM, Sylvester KG, Yang EY, Sheppard D, Herlyn M, Adzick NS.
Epidermal integrin expression is upregulated rapidly in human fetal wound repair. J
Pediatr Surg. 1998;33:312-316. PMID9498408
170. Hsu M-Y, Shih DT, Meier FE, Van Belle P, Hsu JY, Elder DE, Buck CA, Herlyn M.
Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to
vertical growth phase in primary human melanoma. Am J Pathol. 1998;153:1435-1442.
PMID9811334 (PMC1853416)
171. Maul GG, Jensen DE, Ishov AM, Herlyn M, Rauscher FJ 3rd. Nuclear redistribution of
BRCA1 during viral infection. Cell Growth Differ. 1998;9:743-755. PMID9751118
172. Prabhu NS, Somasundaram K, Satyamoorthy K, Herlyn M, El-Deiry WS. p73beta, unlike
p53, suppresses growth and induces apoptosis of human papillomavirus E6-expressing
cancer cells. Int J Oncol. 1998;13:5-9. PMID9625796
173. Rauscher FJ 3rd, Morris JF, Fredericks WJ, Lopez-Guisa J, Balakrishnan C, Jost M,
Herlyn M, Rodeck U. Characterization of monoclonal antibodies directed to the aminoterminus of the WT1, Wilms’ tumor suppressor protein. Hybridoma. 1998;17:191-198.
PMID9627060
18
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
174. Ronai Z, Yang YM, Fuchs SY, Adler V, Sardana M, Herlyn M. ATF2 confers radiation
resistance to human melanoma cells. Oncogene. 1998;16:523-531. PMID9484842
175. Sauter ER, Klein-Szanto AJ, Atillasoy E, Montone KT, Goodrow T, Binder RL, Seykora
JT, Herlyn M. Ultraviolet B-induced squamous epithelial and melanocytic cell changes in
a xenograft model of cancer development in human skin. Mol Carcinog. 1998;23:168-174.
PMID9833777
176. Shih IM, Nesbit M, Herlyn M, Kurman RJ. A new Mel-CAM (CD146)-specific monoclonal
antibody, MN-4, on paraffin-embedded tissue. Mod Pathol. 1998;11:1098-1106.
PMID9831208
177. Easty DJ, Hill SP, Hsu M-Y, Fallowfield ME, Florenes VA, Herlyn M, Bennett DC. Upregulation of ephrin-A1 during melanoma progression. Int J Cancer. 1999;84:494-501.
PMID10502726
178. Ge K, DuHadaway J, Du W, Herlyn M, Rodeck U, Prendergast GC. Mechanism for
elimination of a tumor suppressor: aberrant splicing of a brain-specific exon causes loss
of function of Bin1 in melanoma. Proc Natl Acad Sci U S A. 1999;96:9689-9694.
PMID10449755 (PMC22271)
179. Hsu JY, Hsu M-Y, Sorger T, Herlyn M, Levine EM. Heparin/endothelial cell growth
supplement regulates matrix gene expression and prolongs life span of vascular smooth
muscle cells through modulation of interleukin-1. In Vitro Cell Dev Biol Anim.
1999;35:647-654. PMID10614876
180. Krasilnikov M, Adler V, Fuchs SY, Dong Z, Haimovitz-Friedman A, Herlyn M, Ronai Z.
Contribution of phosphatidylinositol 3-kinase to radiation resistance in human melanoma
cells. Mol Carcinog. 1999;24:64-69. PMID10029412
181. Liechty KW, Nesbit M, Herlyn M, Radu A, Adzick NS, Crombleholme TM. Adenoviralmediated overexpression of platelet-derived growth factor-B corrects ischemic impaired
wound healing. J Invest Dermatol. 1999;113:375-383. PMID10469337
182. Mitra J, Dai CY, Somasundaram K, El-Deiry WS, Satyamoorthy K, Herlyn M, Enders GH.
Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor
p16(INK4a). Mol Cell Biol. 1999;19:3916-3928. PMID10207115 (PMC84249)
183. Moretti S, Pinzi C, Spallanzani A, Berti E, Chiarugi A, Mazzoli S, Fabiani M, Vallecchi C,
Herlyn M. Immunohistochemical evidence of cytokine networks during progression of
human melanocytic lesions. Int J Cancer. 1999;84:160-168. PMID10096249
184. Nesbit M, Nesbit HK, Bennett J, Andl T, Hsu M-Y, DeJesus E, McBrian M, Gupta AR, Eck
SL, Herlyn M. Basic fibroblast growth factor induces a transformed phenotype in normal
human melanocytes. Oncogene. 1999;18:6469-6476. PMID10597249
185. Prabhu NS, Somasundaram K, Tian H, Enders GH, Satyamoorthy K, Herlyn M, El-Deiry
WS. The administration schedule of cyclin-dependent kinase inhibitor gene therapy and
etoposide chemotherapy is a major determinant of cytotoxicity. Int J Oncol. 1999;15:209216. PMID10402229
186. Sauter ER, Nesbit M, Litwin S, Klein-Szanto AJ, Cheffetz S, Herlyn M. Antisense cyclin
D1 induces apoptosis and tumor shrinkage in human squamous carcinomas. Cancer Res.
1999;59:4876-4881. PMID10519399
187. Sauter ER, Nesbit M, Watson JC, Klein-Szanto A, Litwin S, Herlyn M. Vascular
endothelial growth factor is a marker of tumor invasion and metastasis in squamous cell
carcinomas of the head and neck. Clin Cancer Res. 1999;5:775-782. PMID10213212
188. Van Belle PA, Elenitsas R, Satyamoorthy K, Wolfe JT, Guerry DT, Schuchter L, Van Belle
TJ, Albelda S, Tahin P, Herlyn M, Elder DE. Progression-related expression of beta3
integrin in melanomas and nevi. Hum Pathol. 1999;30:562-567. PMID10333228
189. Ayyanathan K, Fredericks WJ, Berking C, Herlyn M, Balakrishnan C, Gunther E,
Rauscher FJ 3rd. Hormone-dependent tumor regression in vivo by an inducible
19
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
transcriptional repressor directed at the PAX3-FKHR oncogene. Cancer Res.
2000;60:5803-5814. PMID11059777
190. Chandler LA, Doukas J, Gonzalez AM, Hoganson DK, Gu DL, Ma C, Nesbit M,
Crombleholme TM, Herlyn M, Sosnowski BA, Pierce GF. FGF2-Targeted adenovirus
encoding platelet-derived growth factor-B enhances de novo tissue formation. Mol Ther.
2000;2:153-160. PMID10947943
191. Fredericks WJ, Ayyanathan K, Herlyn M, Friedman JR, Rauscher FJ 3rd. An engineered
PAX3-KRAB transcriptional repressor inhibits the malignant phenotype of alveolar
rhabdomyosarcoma cells harboring the endogenous PAX3-FKHR oncogene. Mol Cell
Biol. 2000;20:5019-5031. PMID10866659 (PMC85952)
192. Hsu M-Y, Meier FE, Nesbit M, Hsu JY, Van Belle P, Elder DE, Herlyn M. E-cadherin
expression in melanoma cells restores keratinocyte-mediated growth control and downregulates expression of invasion-related adhesion receptors. Am J Pathol.
2000;156:1515-1525. PMID10793063 (PMC1876923)
193. Hsu M, Andl T, Li G, Meinkoth JL, Herlyn M. Cadherin repertoire determines partnerspecific gap junctional communication during melanoma progression. J Cell Sci.
2000;113(Pt 9):1535-1542. PMID10751145
194. Margolis DJ, Crombleholme T, Herlyn M. Clinical protocol: phase I trial to evaluate the
safety of H5.020CMV.PDGF-B for the treatment of a diabetic insensate foot ulcer. Wound
Repair Regen. 2000;8:480-493. PMID11208175
195. Meier F, Nesbit M, Hsu M-Y, Martin B, Van Belle P, Elder DE, Schaumburg-Lever G,
Garbe C, Walz TM, Donatien P, Crombleholme TM, Herlyn M. Human melanoma
progression in skin reconstructs : biological significance of bFGF. Am J Pathol.
2000;156:193-200. PMID10623667 (PMC1868639)
196. Oka M, Berking C, Nesbit M, Satyamoorthy K, Schaider H, Murphy G, Ichihashi M, Sauter
E, Herlyn M. Interleukin-8 overexpression is present in pyoderma gangrenosum ulcers
and leads to ulcer formation in human skin xenografts. Lab Invest. 2000;80:595-604.
PMID10780675
197. Satyamoorthy K, Oka M, Herlyn M. An antisense strategy for inhibition of human
melanoma growth targets the growth factor pleiotrophin. Pigment Cell Res. 2000;13(suppl
8):87-93. PMID11041363
198. Satyamoorthy K, Chehab NH, Waterman MJ, Lien MC, El-Deiry WS, Herlyn M,
Halazonetis TD. Aberrant regulation and function of wild-type p53 in radioresistant
melanoma cells. Cell Growth Differ. 2000;11:467-474. PMID11007451
199. Sauter ER, Herlyn M, Liu SC, Litwin S, Ridge JA. Prolonged response to antisense cyclin
D1 in a human squamous cancer xenograft model. Clin Cancer Res. 2000;6:654-660.
PMID10690551
200. Smedley D, Sidhar S, Birdsall S, Bennett D, Herlyn M, Cooper C, Shipley J.
Characterization of chromosome 1 abnormalities in malignant melanomas. Genes
Chromosomes Cancer. 2000;28:121-125. PMID10738310
201. St John LS, Sauter ER, Herlyn M, Litwin S, Adler-Storthz K. Endogenous p53 gene status
predicts the response of human squamous cell carcinomas to wild-type p53. Cancer
Gene Ther. 2000;7:749-756. PMID10830722
202. Sylvester KG, Nesbit M, Radu A, Herlyn M, Adzick NS, Crombleholme TM. Adenoviralmediated gene transfer in wound healing: acute inflammatory response in human skin in
the SCID mouse model. Wound Repair Regen. 2000;8:36-44. PMID10760213
203. Berking C, Takemoto R, Schaider H, Showe L, Satyamoorthy K, Robbins P, Herlyn M.
Transforming growth factor-beta1 increases survival of human melanoma through stroma
remodeling. Cancer Res. 2001;61:8306-8316. PMID11719464
20
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
204. Berking C, Takemoto R, Satyamoorthy K, Elenitsas R, Herlyn M. Basic fibroblast growth
factor and ultraviolet B transform melanocytes in human skin. Am J Pathol. 2001;158:943953. PMID11238042 (PMC1850339)
205. Doukas J, Chandler LA, Gonzalez AM, Gu D, Hoganson DK, Ma C, Nguyen T, Printz MA,
Nesbit M, Herlyn M, Crombleholme TM, Aukerman SL, Sosnowski BA, Pierce GF. Matrix
immobilization enhances the tissue repair activity of growth factor gene therapy vectors.
Hum Gene Ther. 2001;12:783-798. PMID11339895
206. Herlyn M, Ferrone S, Ronai Z, Finerty J, Pelroy R, Mohla S. Melanoma biology and
progression. Cancer Res. 2001;61:4642-4643. PMID11389102
207. Iida J, Pei D, Kang T, Simpson MA, Herlyn M, Furcht LT, McCarthy JB. Melanoma
chondroitin sulfate proteoglycan regulates matrix metalloproteinase-dependent human
melanoma invasion into type I collagen. J Biol Chem. 2001;276:18786-18794.
PMID11278606
208. Li G, Schaider H, Satyamoorthy K, Hanakawa Y, Hashimoto K, Herlyn M. Downregulation
of E-cadherin and desmoglein 1 by autocrine hepatocyte growth factor during melanoma
development. Oncogene. 2001;20:8125-8135. PMID11781826
209. Li G, Satyamoorthy K, Herlyn M. N-cadherin-mediated intercellular interactions promote
survival and migration of melanoma cells. Cancer Res. 2001;61:3819-3825.
PMID11325858
210. McArdle L, Rafferty M, Maelandsmo GM, Bergin O, Farr CJ, Dervan PA, O’Loughlin S,
Herlyn M, Easty DJ. Protein tyrosine phosphatase genes downregulated in melanoma. J
Invest Dermatol. 2001;117:1255-1260. PMID11710941
211. Nesbit M, Schaider H, Berking C, Shih DT, Hsu M-Y, McBrian M, Crombleholme TM,
Elenitsas R, Buck C, Herlyn M. Alpha5 and alpha2 integrin gene transfers mimic the
PDGF-B-induced transformed phenotype of fibroblasts in human skin. Lab Invest.
2001;81:1263-1274. PMID11555674
212. Nesbit M, Schaider H, Miller TH, Herlyn M. Low-level monocyte chemoattractant protein-1
stimulation of monocytes leads to tumor formation in nontumorigenic melanoma cells. J
Immunol. 2001;166:6483-6490. PMID11359798
213. Satyamoorthy K, Li G, Vaidya B, Patel D, Herlyn M. Insulin-like growth factor-1 induces
survival and growth of biologically early melanoma cells through both the mitogenactivated protein kinase and beta-catenin pathways. Cancer Res. 2001;61:7318-7324.
PMID11585772
214. Satyamoorthy K, Muyrers J, Meier F, Patel D, Herlyn M. Mel-CAM-specific genetic
suppressor elements inhibit melanoma growth and invasion through loss of gap junctional
communication. Oncogene. 2001;20:4676-4684. PMID11498790
215. Sauter ER, Nesbit M, Tichansky D, Liu ZJ, Shirakawa T, Palazzo J, Herlyn M. Fibroblast
growth factor-binding protein expression changes with disease progression in clinical and
experimental human squamous epithelium. Int J Cancer. 2001;92:374-381.
PMID11291074
216. Sauter ER, Tichansky D, Furth EE, Herlyn M. Tumor-associated antigen expression and
growth requirements predict tumorigenesis in squamous cell carcinoma. In Vitro Cell Dev
Biol Anim. 2001;37:530-535. PMID11669287
217. Berking C, Takemoto R, Binder RL, Hartman SM, Ruiter DJ, Gallagher PM, Lessin SR,
Herlyn M. Photocarcinogenesis in human adult skin grafts. Carcinogenesis. 2002;23:181187. PMID11756239
218. Brose MS, Volpe P, Feldman M, Kumar M, Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna
J, Nicholson A, Roth JA, Albelda SM, Davies H, Cox C, Brignell G, Stephens P, Futreal
PA, Wooster R, Stratton MR, Weber BL. BRAF and RAS mutations in human lung cancer
and melanoma. Cancer Res. 2002;62:6997-7000. PMID12460918
21
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
219. Samadi DS, Jacobs IN, Walsh D, Bouchard S, Herlyn M, Crombleholme TM. Adenovirusmediated ex vivo gene transfer of human vascular endothelial growth factor in a rabbit
laryngotracheal reconstruction model. Ann Otol Rhinol Laryngol. 2002;111:295-301.
PMID11991579
220. Satyamoorthy K, Li G, Van Belle PA, Elder DE, Herlyn M. A versatile method for the
removal of melanin from ribonucleic acids in melanocytic cells. Melanoma Res.
2002;12:449-452. PMID12394186
221. Satyamoorthy K, Li G, Vaidya B, Kalabis J, Herlyn M. Insulin-like growth factor-I-induced
migration of melanoma cells is mediated by interleukin-8 induction. Cell Growth Differ.
2002;13:87-93. PMID11864912
222. Sauter ER, Takemoto R, Litwin S, Herlyn M. p53 alone or in combination with antisense
cyclin D1 induces apoptosis and reduces tumor size in human melanoma. Cancer Gene
Ther. 2002;9:807-812. PMID12224020
223. Sauter ER, Yeo UC, von Stemm A, Zhu W, Litwin S, Tichansky DS, Pistritto G, Nesbit M,
Pinkel D, Herlyn M, Bastian BC. Cyclin D1 is a candidate oncogene in cutaneous
melanoma. Cancer Res. 2002;62:3200-3206. PMID12036934
224. Shih IM, Hsu M-Y, Oldt RJ 3rd, Herlyn M, Gearhart JD, Kurman RJ. The role of Ecadherin in the motility and invasion of implantation site intermediate trophoblast.
Placenta. 2002;23:706-715. PMID12398810
225. Sturm RA, Satyamoorthy K, Meier F, Gardiner BB, Smit DJ, Vaidya B, Herlyn M.
Osteonectin/SPARC induction by ectopic beta(3) integrin in human radial growth phase
primary melanoma cells. Cancer Res. 2002;62:226-232. PMID11782382
226. Velazquez OC, Snyder R, Liu ZJ, Fairman RM, Herlyn M. Fibroblast-dependent
differentiation of human microvascular endothelial cells into capillary-like 3-dimensional
networks. Faseb J. 2002;16:1316-1318. PMID12060671
227. Wang E, Miller LD, Ohnmacht GA, Mocellin S, Perez-Diez A, Petersen D, Zhao Y, Simon
R, Powell JI, Asaki E, Alexander HR, Duray PH, Herlyn M, Restifo NP, Liu ET, Rosenberg
SA, Marincola FM. Prospective molecular profiling of melanoma metastases suggests
classifiers of immune responsiveness. Cancer Res. 2002;62:3581-3586. PMID12097256
(PMC2241738)
228. Andl CD, Mizushima T, Nakagawa H, Oyama K, Harada H, Chruma K, Herlyn M, Rustgi
AK. Epidermal growth factor receptor mediates increased cell proliferation, migration, and
aggregation in esophageal keratinocytes in vitro and in vivo. J Biol Chem. 2003;278:18241830. PMID12435727
229. Cook AL, Donatien PD, Smith AG, Murphy M, Jones MK, Herlyn M, Bennett DC, Leonard
JH, Sturm RA. Human melanoblasts in culture: expression of BRN2 and synergistic
regulation by fibroblast growth factor-2, stem cell factor, and endothelin-3. J Invest
Dermatol. 2003;121:1150-1159. PMID14708619
230. Gruss CJ, Satyamoorthy K, Berking C, Lininger J, Nesbit M, Schaider H, Liu ZJ, Oka M,
Hsu M-Y, Shirakawa T, Li G, Bogenrieder T, Carmeliet P, El-Deiry WS, Eck SL, Rao JS,
Baker AH, Bennet JT, Crombleholme TM, Velazquez O, Karmacharya J, Margolis DJ,
Wilson JM, Detmar M, Skobe M, Robbins PD, Buck C, Herlyn M. Stroma formation and
angiogenesis by overexpression of growth factors, cytokines, and proteolytic enzymes in
human skin grafted to SCID mice. J Invest Dermatol. 2003;120:683-692. PMID12648235
231. Hingorani SR, Jacobetz MA, Robertson GP, Herlyn M, Tuveson DA. Suppression of
BRAF(V599E) in human melanoma abrogates transformation. Cancer Res.
2003;63:5198-5202. PMID14500344
232. Hirst CJ, Herlyn M, Cattini PA, Kardami E. High levels of CUG-initiated FGF-2 expression
cause chromatin compaction, decreased cardiomyocyte mitosis, and cell death. Mol Cell
Biochem. 2003;246:111-116. PMID12841351
22
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
233. Kalabis J, Patterson MJ, Enders GH, Marian B, Iozzo RV, Rogler G, Gimotty PA, Herlyn
M. Stimulation of human colonic epithelial cells by leukemia inhibitory factor is dependent
on collagen-embedded fibroblasts in organotypic culture. Faseb J. 2003;17:1115-1117.
PMID12692084
234. Li G, Kalabis J, Xu X, Meier F, Oka M, Bogenrieder T, Herlyn M. Reciprocal regulation of
MelCAM and AKT in human melanoma. Oncogene. 2003;22:6891-6899. PMID14534536
235. Liu ZJ, SnyderR, Soma A, Shirakawa T, Ziober BL, Fairman RM, Herlyn M, Velazquez
OC. VEGF-A and alphaVbeta3 integrin synergistically rescue angiogenesis via N-Ras and
PI3-K signaling in human microvascular endothelial cells. Faseb J. 2003;17:1931-1933.
PMID14519669
236. Liu ZJ, Shirakawa T, Li Y, Soma A, Oka M, Dotto GP, Fairman RM, Velazquez OC,
Herlyn M. Regulation of Notch1 and Dll4 by vascular endothelial growth factor in arterial
endothelial cells: implications for modulating arteriogenesis and angiogenesis. Mol Cell
Biol. 2003;23:14-25. PMID12482957 (PMC140667)
237. Meier F, Caroli U, Satyamoorthy K, Schittek B, Bauer J, Berking C, Moller H, Maczey E,
Rassner G, Herlyn M, Garbe C. Fibroblast growth factor-2 but not Mel-CAM and/or beta3
integrin promotes progression of melanocytes to melanoma. Exp Dermatol. 2003;12:296306. PMID12823444
238. Satyamoorthy K, Li G, Gerrero MR, Brose MS, Volpe P, Weber BL, Van Belle P, Elder
DE, Herlyn M. Constitutive mitogen-activated protein kinase activation in melanoma is
mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res.
2003;63:756-759. PMID12591721
239. Schaider H, Oka M, Bogenrieder T, Nesbit M, Satyamoorthy K, Berking C, Matsushima K,
Herlyn M. Differential response of primary and metastatic melanomas to neutrophils
attracted by IL-8. Int J Cancer. 2003;103:335-343. PMID12471616
240. Song JH, Song DK, Herlyn M, Petruk KC, Hao C. Cisplatin down-regulation of cellular
Fas-associated death domain-like interleukin-1beta-converting enzyme-like inhibitory
proteins to restore tumor necrosis factor-related apoptosis-inducing ligand-induced
apoptosis in human melanoma cells. Clin Cancer Res. 2003;9:4255-4266.
PMID14519653
241. Zhang H, Satyamoorthy K, Herlyn M, Rosdahl I. All-trans retinoic acid (atRA) differentially
induces apoptosis in matched primary and metastatic melanoma cells—a speculation on
damage effect of atRA via mitochondrial dysfunction and cell cycle redistribution.
Carcinogenesis. 2003;24:185-191. PMID12584166
242. Al Moustafa AE, Foulkes WD, Wong A, Jallal H, Batist G, Yu Q, Herlyn M, Sicinski P,
Alaoui-Jamali MA. Cyclin D1 is essential for neoplastic transformation induced by both
E6/E7 and E6/E7/ErbB-2 cooperation in normal cells. Oncogene. 2004;23:5252-5256.
PMID15229656
243. Berking C, Takemoto R, Satyamoorthy K, Shirakawa T, Eskandarpour M, Hansson J,
VanBelle PA, Elder DE, Herlyn M. Induction of melanoma phenotypes in human skin by
growth factors and ultraviolet B. Cancer Res. 2004;64:807-811. PMID14871803
244. Edwards RH, Ward MR, Wu H, Medina CA, Brose MS, Volpe P, Nussen-Lee S, Haupt
HM, Martin AM, Herlyn M, Lessin SR, Weber BL. Absence of BRAF mutations in UVprotected mucosal melanomas. J Med Genet. 2004;41:270-272. PMID15060100
(PMC1735752)
245. Keswani SG, Katz AB, Lim FY, Zoltick P, Radu A, Alaee D, Herlyn M, Crombleholme TM.
Adenoviral mediated gene transfer of PDGF-B enhances wound healing in type I and type
II diabetic wounds. Wound Repair Regen. 2004;12:497-504. PMID15453831
246. Kim, SH, Kim K, Kwagh JG, Dicker DT, Herlyn M, Rustgi AK, Chen Y, El-Deiry WS. Death
induction by recombinant native TRAIL and its prevention by a caspase 9 inhibitor in
23
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
primary human esophageal epithelial cells. J Biol Chem. 2004;279:40044-40052.
PMID15226295
247. Kim JW, Wong CW, Goldsmith JD, Song C, Fu W, Allion MB, Herlyn M, Al-Mehdi AB,
Muschel RJ. Rapid apoptosis in the pulmonary vasculature distinguishes non-metastatic
from metastatic melanoma cells. Cancer Lett. 2004;213:203-212. PMID15327836
248. Li G, Fukunaga M, Herlyn M. Reversal of melanocytic malignancy by keratinocytes is an
E-cadherin-mediated process overriding beta-catenin signaling. Exp Cell Res.
2004;297:142-151; Corrigendum 2005;305:436. PMID15194432
249. Margolis DJ, Cromblehome T, Herlyn M, Cross P, Weinberg L, Filip J, Propert K. Clinical
protocol: phase I trial to evaluate the safety of H5.020CMV.PDGF-b and limb
compression bandage for the treatment of venous leg ulcer: trial A. Hum Gene Ther.
2004;15:1003-1019. PMID15585116
250. van Kempen LC, Meier F, Egeblad M, Kersten-Niessen MJ, Garbe C, Weidle UH, Van
Muijen GN, Herlyn M, Bloemers HP, Swart GW. Truncation of activated leukocyte cell
adhesion molecule: a gateway to melanoma metastasis. J Invest Dermatol.
2004;122:1293-1301. PMID15140234
251. Yang L, Dan HC, Sun M, Liu Q, Sun XM, Feldman RI, Hamilton AD, Polokoff M, Nicosia
SV, Herlyn M, Sebti SM, Cheng JQ. Akt/protein kinase B signaling inhibitor-2, a selective
small molecule inhibitor of Akt signaling with antitumor activity in cancer cells
overexpressing Akt. Cancer Res. 2004;64:4394-4399. PMID15231645
252. Balint K, Xiao M, Pinnix CC, Soma A, Veres I, Juhasz I, Brown EJ, Capobianco AJ,
Herlyn M, Liu ZJ. Activation of Notch1 signaling is required for beta-catenin-mediated
human primary melanoma progression. J Clin Invest. 2005;115:3166-3176.
PMID16239965 (PMC1257536)
253. Fang D, Nguyen TK, Leishear K, Finko R, Kulp AN, Hotz S, Van Belle PA, Xu X, Elder
DE, Herlyn M. A tumorigenic subpopulation with stem cell properties in melanomas.
Cancer Res. 2005;65:9328-9337. PMID16230395
254. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere
M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C,
Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in
human precancerous lesions. Nature. 2005;434:907-913. PMID15829965
255. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. Functional erythropoietin autocrine
loop in melanoma. Am J Pathol. 2005;166:823-830. PMID15743794 (PMC1602342)
256. McArdle L, Rafferty MM, Satyamoorthy K, Maelandsmo GM, Dervan PA, Herlyn M, Easty
DJ. Microarray analysis of phosphatase gene expression in human melanoma. Br J
Dermatol. 2005;152:925-930. PMID15888148
257. Price KL, Herlyn M, Dent CL, Gewert DR, Linge C. The prevalence of interferon-alpha
transcription defects in malignant melanoma. Melanoma Res. 2005;15:91-98.
PMID15846141
258. Smalley KS, Brafford P, Haass NK, Brandner JM, Brown E, Herlyn M. Up-regulated
expression of zonula occludens protein-1 in human melanoma associates with N-cadherin
and contributes to invasion and adhesion. Am J Pathol. 2005;166:1541-1554.
PMID15855653 (PMC1606406)
259. Zhang T, Somasundaram R, Berencsi K, Caputo L, Rani P, Guerry D, Furth E, Rollins BJ,
Putt M, Gimotty P, Swoboda R, Herlyn M, Herlyn D. CXC chemokine ligand 12 (stromal
cell-derived factor 1 alpha) and CXCR4-dependent migration of CTLs toward melanoma
cells in organotypic culture. J Immunol. 2005;174:5856-5863. PMID15843590
260. Fang D, Leishear K, Nguyen TK, Finko R, Cai K, Fukunaga M, Li L, Brafford PA, Kulp AN,
Xu X, Smalley KS, Herlyn M. Defining the conditions for the generation of melanocytes
from human embryonic stem cells. Stem Cells. 2006;24:1668-1677. PMID16574754
24
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
261. Liu ZJ, Xiao M, Balint K, Soma A, Pinnix CC, Capobianco AJ, Velazquez OC, Herlyn M.
Inhibition of endothelial cell proliferation by Notch1 signaling is mediated by repressing
MPAK and PI3K/Akt pathways and requires MAML1. Faseb J. 2006;20:1009-1011.
PMID16571776
262. Liu Z-J, Xiao M, Balint K, Smalley KSM, Brafford P, Qiu E, Pinnix CC, Li X, Herlyn M.
Notch1 signaling promotes primary melanoma progression by activating MitogenActivated Protein Kinase/Phosphatidylinositol 3-kKnase-Akt pathways and upregulating
N-cadherin expression. Cancer Res. 2006;66:4182-4190. PMID16618740
263. Oka M, Norose K, Matsushima K, Nishigori C, Herlyn M. Overexpression of IL-8 in the
cornea induces ulcer formation in the SCID mouse. Br J Ophthalmol. 2006;90:612-615.
PMID16418304 (PMC1857070)
264. Oka M, Nishigori C, Kageshita T, Hsu M-Y, Penmatcha S, Herlyn M. Expression of PKC
isoforms in human melanocytic cells in situ. J Dermatol Sci. 2006;41:157-161.
PMID16406501
265. Smalley KS, Haass NK, Brafford PA, Lioni M, Flaherty KT, Herlyn M. Multiple signaling
pathways must be targeted to overcome drug resistance in cell lines derived from
melanoma metastases. Molec Cancer Therapy. 2006;5:1136-1144. PMID16731745
266. Yu H, Fang D, Kumar SM, Li L, Nguyen TK, Acs G, Herlyn M, Xu X. Isolation of a novel
population of multipotent adult stem cells from human hair follicles. Am J Pathol.
2006;168:1879-1988. PMID16723703 PMC(1606635)
267. Hoek KS, Schlegel NC, Brafford P, Sucker A, Ugurel S, Kumar R, Weber BL, Nathanson
KL, Phillips DJ, Herlyn M, Schadendorf D, Dummer R. Metastatic potential of melanomas
defined by specific gene expression profiles with no BRAF signature. Pig Cell Res.
2006;19:290-302. PMID16827748
268. Spoettl T, Hausmann M, Herlyn M, Gunckel M, Falk W, Herfarth H, Schoelmerich J,
Rogler G. Monocyte chemoattractant protein-1 (MCP-1) inhibits the intestinal-like
differentiation of monocytes. Clin Exp Immunol. 2006;145:190-199. PMID16792690
(PMC1942009)
269. Spoettl T, Hausmann M, Gunckel M, Herfarth H, Herlyn M, Schoelmerich J, Rogler G. A
new organotypic model to study cell interactions in the intestinal mucosa. Eur J
Gastroenterol Hepatol. 2006;18:901-909. PMID16825910
270. Liu J, Kumar SKG, Yu D, Molton SA, McMahon M, Herlyn M, Thomas-Tikhonenko A,
Fuchs SY. Oncogenic BRAF regulates ß-Trep expression and NF-ĸB activity in human
melanoma cells. Oncogene. 2007;26:1954-1958. PMID170001349 (PMC1903341)
271. Dicker DT, Lerner J, Van Belle P, Barth SF, Guerry D 4th, Herlyn M, Elder DE, El-Deiry
WS. Differentiation of normal skin and melanoma using high resolution hyperspectral
imaging. Cancer Biol Ther. 2006;5:1033-1038. PMID16931902
272. Andl CD, Fargnoli BB, Okawa T, Bowser M, Takaoka M, Nakagawa H, Klein-Szanto A,
Hua X, Herlyn M, Rustgi AK. Coordinated functions of E-cadherin and TGFß receptor II in
vitro and in vivo. Cancer Res. 2006;66:9878-9885. PMID17047049 (PMC2996096)
273. Fukunaga-Kalabis M, Martinez G, Liu Z-J, Kalabis J, Mrass P, Weninger W, Firth SM,
Planque N, Perbal B, Herlyn M. CCN3 controls 3D spatial localization of melanocytes in
the human skin through DDR1. J Cell Biol. 2006;175:563-569. PMID17101694
(PMC2064593)
274. Oyama K, Okawa T, Nakagawa H, Takaoka M, Andl C, Kim S-H, Klein-Szanto A, Diehl
JA, Herlyn M, El-Deiry W, Rustgi AK. Akt induces senescence in primary esophageal
epithelial cells but is permissive for differentiation as revealed in organotypic culture.
Oncogene. 2006;26:2353-2364. PMID17043653 (PMC2996093)
275. King AJ, Patrick DR, Batorsky RS, Ho ML, Do HT, Zhang S-Y, Kumar R, Rusnak DW,
Takle AK, Wilson DM, Hugger E, Wang L, Karreth F, Lougheed JC, Lee J, Chau D, Stout
25
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
TJ, May EW, Rominger CM, Schaber MD, Luo L, Lakdawala AS, Adams JL, Contractor
RG, Smalley KAM, Herlyn M, Morrissey MM, Tuveson DA, Huang PS. Demonstration of a
genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor
SB-590885. Cancer Res. 2006;66:11100-11105. PMID17145850
276. Smalley KSM, Contractor R, Haass NK, Kulp AN, Atilla-Gokcumen GE, Williams DS,
Bregman H, Flaherty KT, Soengas MS, Meggers E, Herlyn M. An organometallic protein
kinase inhibitor pharmacologically activates p53 and induces apoptosis in human
melanoma cells. Cancer Res. 2007;67:209-217. PMID17210701
277. Lioni M, Brafford P, Andl A, Rustgi A, El-Deiry W, Herlyn M, Smalley KSM. Dysregulation
of Claudin-7 leads to loss of E-cadherin expression and the increased invasion of
esophageal squamous cell carcinoma cells. Am J Pathol. 2007;170:709-721.
PMID17255337 (PMC1851859)
278. Smalley KS, Contractor R, Haass NK, Lee JT, Nathanson KL, Medina CA, Flaherty KT,
Herlyn M. Ki67 expression levels are a better marker of reduced melanoma growth
following MEK inhibitor treatment than phospho-ERK levels. Brit J Cancer. 2007;96:445449. PMID17210701 (PMC2360037)
279. Meier F, Busch S, Lasithiotakis K, Kulms D, Garbe C, Maczey E, Herlyn M, Schitteck B.
Combining targeting MAPK and AKT signaling pathways is a promising strategy for
melanoma therapy. Br J Derm. 2007;156:1204-1213. PMID17388918
280. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P, Acs G, Herlyn M, Xu X.
Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Cancer Res. 2007;67:3177-3184. PMID17409425
281. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng
W, Zander T, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L,
Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt
A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA,
Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM,
Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F,
Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M,
Garraway LA. High-throughput oncogene mutation profiling in human cancer. Nature
Genet. 2007;39:347-351. PMID17293865; Corrigendum 2007;39:567. PMID17392811
282. Seidl H, Richtig E, Tilz H, Stefan M, Schmidbauer U, Asslaber M, Zatloukal K, Herlyn M,
Schaider H. Profiles of chemokine receptors in melanocytic lesions: de novo expression
of CXCR6 in melanoma. Hum Pathol. 2007;38:768-780. PMID17306330
283. Lopez-Bergami P, Huang C, Goydos JS, Yip D, Bar-Eli M, Herlyn M, Smalley KS, Mahale
A, Eroshkin A, Aaronson S, Ronai Z. Re-wired ERK-JNK signaling pathways in
melanoma. Cancer Cell. 2007;11:447-460. PMID17482134 (PMC1978100)
284. Spittle C, Ward MR, Nathanson KL, Gimotty PA, Rappaport E, Brose MS, Medina A,
Letrero R, Herlyn M, Edwards RH. Application of a BRAF pyrosequencing assay for
mutation detection and copy number analysis in malignant melanoma. J Molec Diagn.
2007;9:464-471. PMID17690212 (PMC1975103)
285. Kumar KGS, Liu J, Yu D, Thomas-Tikhonenko A, Herlyn M, Fuchs SY. Raf inhibitor
stabilizes receptor for type I interferon but inhibits its anti-proliferative effects in human
malignant melanoma cells. Cancer Biol Ther. 2007;6:1437-1441. PMID17873516
(PMC2254442)
286. Wenke AK, Kjellman C, Lundgren-Akerlund E, Uhlmann C, Haass NK, Herlyn M,
Bosserhoff AK. Expression of integrin alpha 10 is induced in melanoma. Cell Oncol.
2007;29:373-386. PMID17726260
287. Lin WM, Baker AC, Beroukhim R, Winkler W, Feng W, Marmion J, Laine E, Greulich H,
Tseng H, Gates C, Hodi FS, Dranoff GM, Sellers WR, Thomas RK, Meyerson M, Golub
26
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
TR, Dummer R, Herlyn M, Getz G, Garraway LA. Modeling genomic diversity and tumor
dependency in malignant melanoma. Cancer Res. 2008;68:664-673. PMID18245465
288. Okawa T, Michaylira CZ, Kalabis J, Stairs DB, Nakagawa H, Andl C, Johnstone CN,
Klein-Szanto AI, El-Deiry WS, Cukierman E, Herlyn M, Rustgi AK. The functional interplay
between EGFR, hTERT activation and p53 mutation in esophageal epithelial cells with
activation of stromal fibroblasts induce tumor development, invasion and differentiation.
Genes Devel. 2007;21:2788-2803. PMID17974918 (PMC2045132)
289. Fukunaga-Kalabis M, Martinez G, Telson SM, Liu Z-J, Balint K, Juhasz I, Elder DE,
Perbal B, Herlyn M. Loss of CCN3 expression as a potential mechanism for melanoma
progression. Oncogene. 2007;27:2552-2558. PMID17968313 (PMC N/A)
290. Han M-J, Herlyn M, Fisher AB, Speicher DW. Microscale solution IEF combined with 2-D
DIGE substantially enhances analysis depth of complex proteomes such as mammalian
cell and tissue extracts. Electrophoresis. 2008;29:695-705. PMID18186533 (PMC N/A)
291. Haass NK, Sproesser K, Nguyen TK, Contractor R, Medina CA, Nathanson KL, Herlyn M,
Smalley KSM. The MEK inhibitor AZD6244 (ARRY-142886) induces growth arrest in
melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res.
2008;14:230-239. PMID18172275 (PMC N/A)
292. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, Bremer R, Gilette S, Kong J, Haass
NK, Sproesser K, Li L, Smalley KSM, Fong D, Zhu Y-L, Marimuthu A, Nguyen H, Lam B,
Liu J, Cheung I, Rice J, Suzuki Y, Liu C, Settachatgul C, Shellooe R, Cantwell J, Kim S-H,
Schlessinger J, Zhang KYJ, West B, Powell B, Habets G, Zhang C, Ibrahim PN, Hirth P,
Artis DR, Herlyn M, Bollag G. Discovery of a novel selective inhibitor of oncogenic B-Raf
kinase with potent anti-melanoma activity. Proc Nat Acad Sc U S A. 2008;26:3041-3049.
PMID18287029 (PMC2268581)
293. Zecchini S, Bianchi M, Colombo N, Fasani R, Goisis G, Casadio C, Viale G, Liu J, Herlyn
M, Godwin A, Nuciforo P, Cavallaro U. The differential role of L1 in normal and
transformed ovarian surface epithelium. Cancer Res.2008;68:1110-1118. PMID18281486
(PMC N/A)
294. Gordon A, Kozin ED, Keswani SG, Vaikunth SS, Katz AB, Zoltick PW, Favata M, Radu
AP, Soslowsky LJ, Herlyn M, Crombleholme TM. Permissive environment in postnatal
wounds by adenoviral-mediated overexpression of the anti-inflammatroy cytokine
interleukin-10 prevents scar formation. Wound Repair Regen. 2008;16:70-79.
PMID18086289 (PMC N/A)
295. Sigalotti L, Covre A, Zabierowski S, Himes B, Colizzi F, Natali PG, Herlyn M, Maio M.
Cancer testis antigens in human melanoma stem cells: expression, distribution and
methylation status. J Cell Physiol. 2008;215:287-291. PMID1802582 (PMC N/A)
296. Noma K, Smalley KSM, Lioni M, Naomoto Y, Tanaka N, El-Deiry W, King AJ, Nakagawa
H, Herlyn M. An essential role for stromal fibroblasts and transformating growth factors
(TGF)-ß in esophageal squamous cell carcinoma-induced angiogenesis. Gastroenterol.
2008;134:1981-1993. PMID18439605 (PMC2562524)
297. Maksimoska J, Williams DS, Atilla-Gokcumen GE, Smalley KSM, Carroll PJ, Webster RD,
Filippakopoulos P, Knapp S, Herlyn M, Meggers E. Isostructural ruthenium and osmium
complexes display highly similar bioactivities. Chemistry. 2008;14:4816-4822.
PMID18425743 (PMC2753370)
298. Alfano RW, Leppla SH, Liu S, Bugge TH, Herlyn M, Smalley KS, Duesberg NS, Houghton
A, Frankel AE. Cytotoxicity of the engineered matrix metalloproteinase-activated anthrax
lethal toxin is dependent on gelatinase expression and B-RAF status in human melanoma
cells. Molec Cancer Therap. 2008;8:1218-1226. PMID18483309 (PMC2757055)
27
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
299. Kalabis J, Li G, Fukunaga-Kalabis M, Rustgi A, Herlyn M. Endothelin-3 stimulates survival
of goblet cells in organotypic cultures of human colonic epithelium. Am J Physiol - GI
Liver Physiol. 2008;295:G1182-1189. PMID18832450 (PMC2604801)
300. Smalley KSM, Contractor R, Nguyen TK, Xiao M, Medinca A, Edwards R, Muthusamy V,
King AJ, Flaherty KT, Bosenberg M, Herlyn M, Nathanson KL. Identification of a novel
sub-group of melanomas with kit/cyclin-dependent kinase-4 overexpression. Cancer Res.
2008;68:5743-5752. PMID18632627 (PMC2615688)
301. Xie P, Williams DS, Atilla Gokumen GE, Milk L, Xiao M, Smalley KS, Herlyn M, Meggers
E, Marmorstein R. Structure-based design of an organoruthenium phosphotidyl-inositol-3kinase inhibitor revieals a switch governing lipid kinase potency and selectivity. ACS
Chem Biol. 2008;3:305-316. PMID18484710 (PMC3618672)
302. Smalley KSM, Lioni M, Palma MD, Xiao M, Desai B, Eghazi S, Hansson J, Hong W, King
AJ, Flaherty KT, Herlyn M, Nathanson KL. Cyclin D1 mediates BRAF inhibitor resistance
in a sub-set of BRAF-V600E mutated melanomas. Molec Can Ther. 2008;7:2876-2883.
PMID18790768 (PMC2651569)
303. Lioni M, Noma K, Snyder A, Rustgi A, Diehl JA, Herlyn M, Smalley K. Bortezomib-induced
cellular stress via the p38 MAPK pathway leads to a DNA damage response and
apoptosis in esophageal squamous cell carcinoma cells. Molec Cancer Ther.
2008;7:2866-2875. PMID18790767 (PMC2903039)
304. Harada H, Nakagawa H, Takaoka M, Lee J, Herlyn J, Diehl JA, Rustgi AK. Cleavage of
MCM2 licensing proteins fosters senescence in human keratinocytes. Cell Cycle.
2008;7:3534-3538. PMID19001876 (PMC2736109)
305. Kalabis J, Oyama K, Okawa T, Nakagawa H, Michaylira CZ, Stairs DB, Figueiredo JL,
Mahmood U, Diehl JA, Herlyn M, Rustgi AK. A sub-population of mouse esophageal
basal cells has properties of stem cells with the capacity for self-renewal and lineage
specification. J Clin Invest. 2008;118:3860-3869. PMID19005570 (PMC2579884)
306. Smalley KSM, Xiao M, Villanueva J, Nguyen TK, Flaherty KT, Letrero R, Nathanson KL,
Herlyn M. CRAF inhibition induces Bcl-2 dependent apoptosis in melanomas with non
V600E BRAF mutations. Oncogene. 2009;28:85-94. PMID18794803 (PMC2898184)
307. Greshok J, Nathanson K, Medina A, Ward MR, Herlyn M, Weber BL, Zaks TZ. Distinct
patterns of DNA copy number alterations associate with BRAF mutations in melanomas
and melanoma derived cell lines. Genes, Chromosomes, Cancer. 2009;48:419-428.
PMID19226609 (PMC2885833)
308. Yu H, McDaid R, Lee J, Possik P, Kumar SM, Elder DE, Van Belle P, Gimotty P, Guerra
M, Hammond R, Nathanson KL, Dalla Plama M, Herlyn M, Xu X. Role of BRAF mutation
and p53 inactivation during transformation of a sub-population of primary human
melanocytes. Am J Pathol. 2009;174:2367-2377. PMID19389934 (PMC2684200)
309. Pinnix CC, Lee JT, Liu Z-J, McDaid R, Balint K, Beverly LJ, Brafford PA, Xiao M, Himes
B, Zabierowski SE, Yashiro-Ohtani Y, Nathanson KL, Bengston A, Pollock PM,
Weeraratna AT, Nickoloff BJ, Pear WE, Capobianco AJ, Herlyn M. Active Notch1 protein
confers a transformed phenotype to primary human melanocytes. Cancer Res.
2009;69:5312-5320. PMID19549918 (PMC2755513)
310. Degenhardt Y, Huang J, Horiates G, Nathanson K, Yang X, Herlyn M, Weber B. Distinct
MHC gene expression patterns during progression of melanoma. Genes, Chromosomes,
Cancer. 2010;49:144-154. PMID19907984 (PMC2796267)
311. Katz AB, Keswani SG, Habli M, Lim FY, Zoltick PW, Midrio P, Kozin ED, Herlyn M,
Crombleholme TM. Placental gene transfer: transgene screening in mice for trophic
effects on the placenta. Am J Obstet Gynocol. 2009;201:499.e1-8. PMID19716119.
(PMC2885953)
28
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
312. Li L, Fukunaga-Kalabis M, Yu H, Xu X, Kong J, Lee JT, Herlyn M. Human dermal stem
cells differentiate into functional epidermal melanocytes. J Cell Sci. 2010;123:853-860.
PMID20159965 (PMC2831759)
313. Ohashi S, Natsuizaka M, Wong GS, Michaylira CZ, Grugan KD, Nakagawa N, KleinSzanto AJ, Herlyn M, Diehl JA, Rustgi AK, Nakagawa H. EGFR and mutant p53 expand
esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition
through ZEB transcription factors. Cancer Res. 2010;70:4174-4184. PMID20424117
(PMC3007622)
314. Basu D, Nguyen T-T, Montone KT, Zhang G, Wang L-P, Diehl JA, Rustgi AK, Lee JT,
Weinstein GS, Herlyn M. Mesenchymal sub-populations within squamous cell carcinomas
exhibiting chemoresistance and phenotypic plasticity. Oncogene. 2010;29:4170-4182.
PMID20498638 (PMC3039880)
315. Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Vultur A,
Basu D, Gimotty P, Vogt T, Herlyn M. A temporarily distinct subpopulation of slow-cycling
melanoma cells is required for continuous tumor growth. Cell. 2010;141:583-594.
PMID204782552 (PMC2882693).
316. Natsuizaka M, Ohashi S, Wong G, Ahmadi A, Kalman R, Budo D, Klein-Szanto A, Herlyn
M, Diehl A, Nakagawa H. Insulin-like growth factor binding protein-3 promotes
transforming growth factor-ß1-mediated epithelial-to-mesenchymal transition and motility
in transformed human esophageal cells. Carcinogenesis. 2010;31:1344-1353.
PMID20513670 (PMC2915630)
317. Michaylira CZ, Wong GS, Miller CG, Gutierrez CM, Nakagawa H, Hammond R, KleinSzanto AJ, Lee JS, Kim SB, Herlyn M, Diehl JA, Gimotty P, Rustgi AK. Periostin, a cell
adhesion molecule, facilitates invasion in the tumor microenvironment and annotates a
novel tumor-invasive signature in esophageal cancer. Cancer Res. 2010;70:5281-5291.
PMID20516120 (PMC3274349)
318. Grugan KD, Miller CG, Yao Y, Michaylira CZ, Ohashi S, Klein-Szanto AJ, Diehl JA, Herlyn
M, Han M, Nakagawa H, Rustgi AK. Fibroblast-secreted hepatocyte growth factor plays a
functional role in esophageal cell carcinoma invasion. Proc Natl Acad Sci U S A.
2010;107:11026-11031. PMID20534479 (PMC2890722)
319. Ohashi S, Natsuizaka M, Yashiro-Ohtani Y, Kalman RA, Nakagawa M, Wu L, KleinSzanto AJ, Herlyn M, Diehl JA, Kathz JP, Pear WS, Seykora JT, Nakagawa H. NOTCH1
and NOTCH3 coordinate esophageal squamous differentiation through a CSL-dependent
transcriptional network. Gastroenterol. 2010;139:2113-2123. PMID20801121
(PMC2997138)
320. Fukunaga-Kalabis M, Martinez G, Nguyen T-TK, Kim D, Santiago-Walker A, Roesch A,
Herlyn M. Tenascin promotes melanoma progression by maintaining the ABCB5-positive
side population. Oncogene. 2010;29:6115-6124. PMID2072997 (PMC2991494)
321. Aggarwal P, Vaites LP, Kim JK, Mellert H, Nakagawa H, Herlyn M, Rustgi A, McMahon
SB, Diehl JA. Nuclear Cyclin D1/CDK4 minase regulates CUL4 expression and triggers
neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell.
2010;18:329-340. PMID20951943 (PMC2957477)
322. Lee J, Li L, Brafford P, Sproesser K, Haass N, Smalley K, van den Eijnden M, Halloran M,
Tsai J, Bollag G, Herlyn M. PLX4032, a potent inhibitor of the B-Raf V600E oncogene,
selectively inhibitrs V600E-positive melanomas. Pig Cell Mel Res. 2010;23:820-827.
PMID20973932 (NIHMS452487, PMC in Progress)
323. Han M-J, Wang H, Beer LA, Tang H-Y, Herlyn M, Speicher D. A systems biology analysis
of metastatic melanoma using in-depth three-dimensional protein profiling. Proteomics.
2010;10:4450-4462. PMID21082759 (PMC3070844)
29
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
324. Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK,
Wubenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D’Andrea K,
Pushparajan A, Hayden JE, Dahlman K, Laquerre S., McArthur G, Sosman J, Nathanson
KL, Herlyn M. Acquired resistance to BRAF inhibitors mediated by an A/B/C RAF kinase
switch in melanoma can be overcome by co-targeting MEK and IGF-1R/PI3K. Cancer
Cell. 2010;18:683-695. PMID21156289 (PMC3026446)
325. Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker
E, Leonard JH, Herlyn M, Sturm RA. Inverse expression of BRN2 and MITF transcription
factors in melanoma spheres and tumor xenografts regulate the NOTCH pathway.
Oncogene. 2011;30:3036-3048. PMID21358674 (PMC3591523)
326. Magnitsky S, Roesch A, Herlyn M, Glickson JD. In vivo and ex vivo MR imaging of slowly
cycling melanoma cells. Magn Reson Med. 2011;66:1362-1372. PMID21523820
(PMC3145816)
327. Basu D, Montone KT, Wang L-P, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT,
Rasanen K, Weinstein GS, Herlyn M. Detecting and targeting mesenchymal-like
subpopulations within squamous cell carcinomas. Cell Cycle. 2011;10:2008-2016.
PMID21558812 (PMC3154419)
328. Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct
model: a tool to study normal skin and melanoma progression. J Vis Exp. 2011;54:e2937.
PMID21847077 (PMC3159964)
329. Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA,
Nakagawa M, Darling DS, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M,
Nakagawa H. A NOTCH3-mediated squamous cell differentiation program limits
expansion of EMT competent cells that express the ZEB transcription factors. Cancer
Res. 2011;71:6636-6847. PMID21890822 (PMC3206139)
330. Blanck S, Cruchter T, Vultur A, Riedel R, Harms K, Herlyn M, Meggers E. Organometallic
pyridylnaphthalimide complexes as protein kinase inhibitors. Organometallics.
2011;30:4598-4606. PMID21918590 (PMC3170819)
331. Flach EH, Rebecca VW, Herlyn M, Smalley KSM, Anderson ARA. Fibroblasts contribute
to melanoma tumor growth and drug resistance. Molecular Pharm. 2011;8:2039-2049.
PMID22067046 (PMC3235959)
332. Feng Y, Barile E, De SK, Stebbins JL, Cortez A, Aza-Blanc P, Villanueva J, Herlyn M,
Krajewski S, Melecchia M, Ronai ZA, Chiang GG. Effective inhibition of melanoma by BI69A11 is mediated by dual targeting of the AKT and NF-kB pathways. Pigm Cell Mel Res.
2011;24:703-713. PMID21592316 (PMC3076536)
333. Kalabis J, Wong GS, Vega ME, Natsuizaka M, Robertson ES, Herlyn M, Nakagawa H,
Rustgi AK. Isolation and characterization of mouse and human esophageal epithelial cells
in 3D organotypic culture. Nature Protocols. 2012;7:235-246. PMID22240585
(PMC3505594)
334. Pinc A, Somasundaram R, Wagner C, Hörmann M, Karanikas G, Jalili A, Bauer W,
Brunner P, Grabmeier-Pfisterhammer K, Gschaider M, Lai CY, Hsu M-Y, Herlyn M, Stingl
G, Wagner SN. Targeting CD20 in melanoma patients at high risk of disease recurrence.
Mol Ther. 2012;20:1056-1062. PMID22354376 (PMC3345981)
335. Wenzel V, Roedl D, Gabriel D, Gordon LB, Herlyn M, Schneider R, Ring J, Djabali K.
Naïve adult stem cells from patients with Hutchinson-Gilford progeria syndrome express
low levels of progerin in vivo. Biol Open. 2012;1:516-526. PMID23213444 (PMC3509444)
336. Wang T, Ge Y, Xiao M, Lopez-Coral A, Azuma R, Somasundaram R, Zhang G, Wei Z, Xu
X, Rauscher FJ, Herlyn M, Kaufman RE. Melanoma-derived conditioned media efficiently
induce the differentiation of monocytes to macrophages that display a highly invasive
gene signature. Pigm Cell Mel Res. 2012;25:493-505. PMID22498258 (PMC3615702)
30
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
337. Qin J, Xie P, Ventocilla C, Zhou G, Vultur A, Chen Q, Liu Q, Herlyn M, Winkler JD,
Marmorstein R. Identification of a novel family of BRAFV600E inhibitors. J Med Chem.
2012;55:5220-5230. PMID22537109 (PMC3383862)
338. Furney SJ, Turajlic S, Fenwick K, Lambros MB, Mackay A, Ricken G, Mitsopoulos C,
Kozarewa I, Hakas J, Zvelebil M, Lord CJ, Ashworth A, Reis-Filho JS, Herlyn M, Murata
H, Marais R. Genomic characterisation of acral melanoma cell lines. Pigment Cell Mel
Res. 2012;25:488-492. PMID22578220 (PMC – N/A)
339. John JK, Paraiso KHT, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E,
Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley
KSM. GSK3ß inhibition blocks melanoma cell/host interactions by downregulating Ncadherin expression and decreasing FAK phosphorylation. J Invest Dermatol.
2012;132:2818-2827. PMID22810307 (PMC3479306)
340. Naganuma S, Whelan KA, Natsuizaka S, Kinugasa H, Chang S, Subramanian H,
Rhoades B, Ohashi S, Itoh H, Herlyn M, Diehl JA, Gimotty PA, Klein-Szanto AJ,
Nakagawa H. Notch receptor inhibition reveals the importance of cyclin D1 and Wnt
signaling in invasive esophageal squamous cell carcinoma. Am J Cancer Res.
2012;2:459-475. PMID22860235 (PMC3410579)
341. Tchou J, Kossenkov AV, Chang L, Satija C, Herlyn M, Showe LC, Puré E. Human breast
cancer associated fibroblasts exhibit subtype specific gene expression profiles. BMC Med
Genomics. 2012;5:39. PMID22954256 (PMC3505468)
342. Chae YC, Caino MC, Lisanti S, Gosh JC, Dohi T, Danial NN, Villanueva J, Ferrero S,
Vaira V, Santambrogio L, Bosari S, Languino LR, Herlyn M, Altieri DC. Control of tumor
bioenergetics and survival stress signaling by mitochondrial HSP90. Cancer Cell.
2012;22:331-344. PMID22975376 (PMC3615709)
343. Kong X, Qin J, Li Z, Vultur A, Tong L, Feng E, Rajan G, Liu S, Lu J, Liang Z, Zheng M,
Zhu W, Jiang H, Herlyn M, Liu H, Marmorstein R, Luo C. Development of a novel class of
B-RAF (V600E)-selective inhibitors through virtual screening and hierarchical hit
optimization. Org Biomol Chem. 2012;10:7402-7417. PMID22875039 (PMC3427755)
344. Schayowitz A, Bertenshaw G, Jeffries E, Schatz T, Cotton J, Villanueva J, Herlyn M,
Krepler C, Vultur A, Xu W, Yu GH, Schuchter L, Clark DP. Functional profiling of live
melanoma samples using a novel automated platform. PLos One. 2012;7:e52760.
PMID23285177 (PMC3532357)
345. Balaburski GM, Leu JI, Beeharry N, Hayik S, Andrake MD, Zhang G, Herlyn M, Villanueva
J, Dunbrack RL, Yen T, George DL, Murphy ME. A modified HSP70 inhibitor shows broad
activity as an anticancer agent. Mol Cancer Res. 2013;11:219-229. PMID23303345
(PMC3606282)
346. Krepler C, Chunduru SK, Halloran MB, He X, Xiao M, Vultur A, Villanueva J, Mitsuuchi Y,
Neiman EM, Benetatos C, Nathanson KL, Amaravadi RK, Pehamberger H, McKinlay M,
Herlyn M. The novel SMAC inhibitor birinapant exhibits potent activity against human
melanoma cells. Clin Cancer Res. 2103;19:1784-1794. PMID23403634 (PMC3618595)
347. Kastl A, Dieckman S, Wähler K, Völker T, Kastl L, Shannan B, Harms K, Ocker M, Parak
W, Herlyn M, Meggers E. Rhenium complexes with visible-light-induced anticancer
activity. Organometallic Med Chem. 2013;8:924-927. PMID23568508 (PMC3665699)
348. Desai BM, Villanueva J, Nguyen T-TK, Lioni M, Xiao M, Kong J, Krepler C, Vultur A,
Flaherty KT, Nathanson KL, Smalley KSM, Herlyn M. The anti-melanoma activity of
dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signaling. PLoS One.
2013;8(3):e59588. PMID23527225 (PMC3601112)
349. Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Li L, Gimotty P, Wilson M, Hayden J,
Keeney F, Nathanson KL, Herlyn M. MEK inhibition affects STAT3 signaling and invasion
in human melanoma cell lines. Oncogene. 2013 April 29 [Epub ahead of print].
31
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
PMID23624919 (PMC3769503)
350. Aird KM, Zhang G, Li H, Tu Z, Bitler BG, Garipov A, Wu H, Wei Z, Wagner SN, Herlyn M,
Zhang R. Suppression of nucleotide metabolism underlies the establishment and
maintenance of oncogene-induced senescence. Cell Rep. 2013;3:1-4. PMID23562156
(PMC3840499 [Available on 2014/4/25]; NIHMS466586)
351. Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke
MW, Gimotty PA, Philipp SE, Krause E, Pätold S, Villanueva J, Krepler C, FukunagaKalabis M, Hoth M, Bastian B, Vogt T, Herlyn M. Overcoming intrinsic multi-drug
resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling
JARID1B(high) cells. Cancer Cell. 2013;23:811-825. PMID23764003 (PMC3810180
[Available on 2014/6/10])
352. Reuveni H, Flashner-Abramson E, Steiner L, Makedonski K, Song R, Shir A, Herlyn M,
Bar-Eli M, Levitzki A. Therapeutic destruction of insulin receptor substrates for cancer
treatment. Cancer Res. 2013;73:4383-4394. PMID23651636
353. Kwak J, Gallagher M, Ozdener MH, Wysocki CJ, Goldsmith BR, Isamah A, Faranda A,
Fakharzadeh SS, Herlyn M, Johnson ATC, Preti G. Volatile biomarkers from human
melanoma cells. J Chromatography B Analyt Technol Biomed Life Sci. 2013;931:90-96.
PMID23770738
354. Villanueva J, Infante J, Krepler C, Reyes-Uribe P, Samanta M, Chen H-Y, Li B, Swoboda
R, Wilson M, Vultur A, Fukunaga-Kalabis M, Wubbenhorst B, Chen TY, Liu Q, Sproesser
K, DeMarini D, Gilmer T, Martin A-M, Marmorstein R, Schultz D, Speicher D, Karakousis
G, Xu W, Amaravadi R, Xu X, Schuchter L, Herlyn M, Nathanson K. Concurrent MEK2
mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in
melanoma. Cell Reports. 2013;4:1090-1099. PMID24055054
355. Basu D, Bewley AF, Sperry SM, Montone KT, Gimotty PA, Rasanen K, Facompre ND,
Weinstein GS, Nakagawa H, Diehl JA, Rustgi AK, Herlyn M. EGFR inhibition promotes an
aggressive invasion pattern mediated by mesenchymal-like tumor cells within squamous
cell carcinomas. Molec Cancer Ther. 2013;12:2176-2186. PMID23939378 (PMC3796003
[Available on 2014/10/1])
356. Lee EK, Lian Z, D'Andrea K, Letrero R, Sheng W, Liu S, Diehl N, Barbash O, Schuchter
LM, Amaravadi RK, Xu X, Herlyn M, Nathanson KL, Diehl JA. The FBXO4 tumor
suppressor functions as a barrier to BRAFV600E-dependent metastatic melanoma. Mol
Cell Biol. 2013;33:4422-4433. PMID24019069
357. Rasänen K, Speicher K, Valiga A, Tang H-Y, Zhang G, Perego M, Somasundaram R, Li
L, Sriwasdi S, Klein-Szanto A, Basu D, Rustgi AK, Speicher DW, Herlyn M. Comparative
secretome analysis of epithelial and mesenchymal subpopulations of head and neck
squamous cell carcinoma identifies S100A4 as a potential therapeutic target. Molec Cell
Proteomics. 2013;12(12):3778-92. PMID24037664
358. Wang T, Ge Y, Xiao M, Lopez-Coral A, Li L, Roesch A, Huang C, Alexander P, Vogt T,
Xu X, Hwang W-T, Lieu M, Belser E, Liu R, Somasundaram R, Herlyn M, Kaufman RE.
SECTM1 produced by tumor cells attracts human monocytes via CD7-mediated
activation of the PI3K pathway. J Invest Dermatol. 2013 Oct 24 [Epub ahead of print].
PMID24157461
359. Wong GS, Lee JS, Park YY, Klein-Szanto AJ, Waldron TJ, Cukierman E, Herlyn M,
Gimotty P, Nakagawa H, Rustgi AK. Periostin cooperates with mutant p53 to mediate
invasion through the induction of STAT1 signaling in the esophagus tumor
microenvironment. Oncogenesis. 2013;2:e59. PMID23917221 (PMC3759121)
360. O'Connell M, Marchbank K, Webster M, Valiga A, Kaur A, Vultur A, Li L, Herlyn M,
Villanueva J, Liu Q, Yin X, Widura S, Nelson J, Ruiz N, Camilli T, Indig FE, Flaherty K,
Wargo J, Frederick DT, Cooper Z, Nair S, Amaravadi R, Schuchter L, Karakousis G, Xu
32
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
W, Xu X, Weeraratna AT. Hypoxia induces phenotypic plasticity and therapy resistance in
melanoma via the tyrosine kinase receptors ROR1 and ROR2. Cancer Discovery.
2013;3(12):1378-93. PMID24104062
361. Nallet-Staub F, Marsaud V, Li L, Gilbert C, Dodier S, Bataille V, Sudol M, Herlyn M,
Mauviel A. Pro-invasive activity of the hippo pathway effectors YAP and TAZ in
cutaneous melanoma. J Invest Dermatol. 2014;134:123-132. PMID23897276
362. Ma X-H, Pioa S-F, Dey S, Mcafee Q, Karakousis G, Villanueva J, Hart LS, Levi S, Hu J,
Zhang G, Lazova R, Klump V, Pawelek JM, Xu X, Schuchter LM, Davies MA, Herlyn M,
Winkler J, Koumenis C, Amaravadi RK. Targeting ER stress induced autophagy
overcomes resistance to BRAF inhibition in melanoma. J Clin Invest. In press.
363. Hayashizaki Y, Forrest A, Kawaji H, Rehli M, Baillie J, de Hoonn M, haberle V, Lassmann
T, Kulakovskiy I, Lizio M, Itoh M, Andersson R, Mungall C, Meehan T, Freeman T,
Schmeier S, Bertin N, Jørgensen M, Dimont E, Arner E, Schaefer U, Medvedeva Y,
Taylor M, Francescatto M, Vitezic M, Severin J, Semple C, Ishizu Y, Kaiho A, Saka A,
Hasegawa A, Knox A, Mackay-Sim A, Edge A, Bonetti A, Diehl A, Favorov A, Meynert A,
Saxena A, Joshi A, Califano A, Lennartsson A, Gibson A, Kwon A, Schwegmann A,
Beckhouse A, Mathelier A, Blumenthal A, Sajantila A, Pain A, Kasianov A, Kubosaki A,
Manabe R, Bodega B, Marchand B, Jankovich B, Cannistraci CV, Davis C, Furlanello C,
Plessy C, Kai C, Schmidl C, Wells C, Mummery C, Schneider C, Sugiyama D, Goldowitz
D, de Lima Morais D, Albanese D, Vijayan D, Ovchinnikov D, Valen E, Dalla E, Wood E,
Saijyo E, Schultes E, van Nimwegen E, Wolvetangg E, Drabløs D, Brombacher F, Hori F,
Nakahara F, Altschuler G, Faulkner G, Jurman G, Schulze-Tanzil G, Sheng G, Fang H,
Clevers H, Koseki H, Persson H, Enomoto H, Tatsukawa H, Sato H, Ohmiya H, Morikawa
H, Nishiyori H, Satoh H, Toyoda H, Kawamoto H, Ohno H, Tanaka H, Carbajo D, Shimoji
H, Motohashi H, Jia H, Hoof I, Vorontsov I, Alam I, Briggs J, Prendergast J, Shin J,
Harshbarger J, Laros J, Mar J, Archer J, Ramilowski J, Blake J, Kempfle J, Kere J, Gough
J, Takai J, Furusawa J, Li K, Kaida K, Ekwall K, Kajiyama K, Moro K, Iida K, Hitchens K,
Nakazato K, Summers K, Lipovich L, Khachigian L, Winteringham L, Huminiecki L,
Babina M, Fisher M, Rashid M, van de Wetering M, Chierici M, Roncador M, Patrikakis M,
Okada-Hatakeyama M, Thompson M, Frith M, Farach-Carson M, Furuno M, Hamaguchi
M, Suzuki M, Yamamoto M, Harbers M, Edinger M, Burroughs AM, Herlyn M, Detmar M,
Fagiolini M, Tagami M, Kojima M, Yoneda M, Endoh M, Ohshima M, Hara M, Morimoto
M, Murata M, Sakai M, Rye M, Kanamori-Katayama M, Ohkura N, Takahashi N, Kondo N,
Mejhert N, Ninomiya N, Hofmann O, Rackham O, Rizzu P, 't Hoen P, Arner P, Zhang P,
Klinken P, Balwierz P, Guler R, Fujita R, Passier R, Verardo R, Swoboda R, Kato S,
Baker S, Krampitz S, Nagao-Sato S, Ho Sui S, Yoshida S, Koyasu S, Sakaguchi S,
Katayama S, Fukuda S, Noma S, Watanabe S, Kawaguchi S, Piazza S, Zucchelli S,
Kojima S, Ogishima S, Gustincich S, Roy S, Zabierowski S, Savvi S, Guhl S, Pradhan
Bhatt S, Nozaki T, Dohi T, Sugiyama T, Hashimoto T, Toyoda T, Geijtenbeek T, Sengstag
T, Gingeras T, Ha T, Ravasi T, Ikawa T, Kenna T, Kitamura T, Nakamura T, Kawashima
T, Orlando V, Lee W, Wasserman W, Zhao W, Ciani Y, Okazaki Y, Shimoni Y, Yonekura
Y, Yamaguchi Y, Mizuno Y, Hasegawa Y, Kawamura Y, Nakamura Y, Chen Y, Nakachi
Y, Tatum Z, Suzuki H, Daub C, Kawai J, Heutink P, Hide W, Lenhard B, Bajic V, Makeev
V, Sandelin A, Hume D, Carninci P, van den Berg L, Fairbairn L, Kaczkowski B, Lilje B,
Simon C, Motakis E, Kasukawa T, Arakawa T, Suzuki N, Young R. A promoter level
mammalian expression atlas. Nature. In press.
Research Publications, Peer-Reviewed Reviews
1. Koprowski H, Herlyn M. Human tumor antigens. In: Wahren B, ed. Molecular Biology of
Tumor Cells. Raven Press; 1985:123-138.
33
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
20.
21.
22.
23.
Ross AH, Herlyn M, Maul GG, Koprowski H, Bothwell M, Chao M, Pleasure D,
Sonnenfeld KH. The nerve growth factor receptor in normal and transformed neural crest
cells. Ann N Y Acad Sci. 1986;486:115-123. PMID3032054
Herlyn M, Clark WH, Rodeck U, Mancianti ML, Jambrosic J, Koprowski H. Biology of
tumor progression in human melanocytes. Lab Invest. 1987;56:461-474. PMID3553733
Herlyn M, Rodeck U, Koprowski H. Shedding of human tumor-associated antigens in vitro
and in vivo. Adv Cancer Res. 1987;49:189-221. PMID3314394
Herlyn M, Clark WHJ. Human melanoma: biology of tumor progression. The Melanoma
Letter. 1987;5:3-4.
Rodeck U, Menssen HD, Herlyn M. Growth factors in the pathogenesis of malignant
diseases. Dtsch Med Wochenschr. 1988;113:904-906. PMID3286186
Herlyn M, Koprowski H. Melanoma antigens: immunological and biological
characterization and clinical significance. Annu Rev Immunol. 1988;6:283-308.
PMID3289568
Rodeck U, Herlyn M. Characteristics of cultured human melanocytes from different stages
of tumor progression. Cancer Treat Res. 1988;43:3-16. PMID2908575
Kath R, Herlyn M. Molecular biology of tumor antigens. Curr Opin Immunol. 1989;1:863866. PMID2679733
Williams NN, Daly JM, Herlyn M. Primary colorectal carcinoma cell lines contain
subpopulations with invasive properties. Surgical Forum. 1989;40:400-403.
Herlyn M, Menrad A, Koprowski H. Structure, function, and clinical significance of human
tumor antigens. J Natl Cancer Inst. 1990;82:1883-1889. PMID2250310
Herlyn M. Human melanoma: development and progression. Cancer Metastasis Rev.
1990;9:101-112. PMID2253310
Herlyn M, Kath R, Williams N, Valyi-Nagy I, Rodeck U. Growth-regulatory factors for
normal, premalignant, and malignant human cells in vitro. Adv Cancer Res. 1990;54:213234. PMID2404378
Valyi-Nagy I, Herlyn M. Melanocyte maturation and differentiation. Lab Invest.
1990;63:276-277.
Herlyn M, Malkowicz SB. Regulatory pathways in tumor growth and invasion. Lab Invest.
1991;65:262-271. PMID1890806
Rodeck U, Becker D, Herlyn M. Basic fibroblast growth factor in human melanoma.
Cancer Cells. 1991;3:308-311. PMID1931440
Rodeck U, Herlyn M. Growth factors in melanoma. Cancer Metastasis Rev. 1991;10:89101. PMID1873858
Herlyn D, Linnenbach A, Koprowski H, Herlyn M. Epitope- and antigen-specific cancer
vaccines. Int Rev Immunol. 1991;7:245-257. PMID1779173
Valyi-Nagy IT, Herlyn M. Regulation of growth and phenotype of normal human
melanocytes in culture. Cancer Treat Res. 1991;54:85-101. PMID1673861
Herlyn D, Adachi K, Koprowski H, Herlyn M. Experimental model of human melanoma
metastases. Cancer Treat Res. 1991;54:105-118. PMID1673854
Graeven U, Rodeck U, Weinmann R, Herlyn M. Stable transfection of human malignant
melanoma cells with basic fibroblast growth factor antisense cDNA. Ann N Y Acad Sci.
1992;660:293-294. PMID1340139
Graeven U, Herlyn M. In vitro growth patterns of normal human melanocytes and
melanocytes from different stages of melanoma progression. J Immunother. 1992;12:199202. PMID1445812
Menrad A, Herlyn M. Tumor progression, biology, and host response in melanoma. Curr
Opin Oncol. 1992;4:351-356. PMID1591308
34
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
24. Elder DE, Herlyn M. Antigens associated with tumor progression in melanocytic
neoplasia. Pigment Cell Res. 1992;3(suppl 2):136-143. PMID1409415
25. Shih IM, Herlyn M. Role of growth factors and their receptors in the development and
progression of melanoma. J Invest Dermatol. 1993;100:196S-203S. PMID8381840
26. Soballe PW, Herlyn M. Cellular pathways leading to melanoma differentiation: therapeutic
implications. Melanoma Res. 1994;4:213-223. PMID7950357
27. Herlyn M, Shih IM. Interactions of melanocytes and melanoma cells with the
microenvironment. Pigment Cell Res. 1994;7:81-88. PMID8066024
28. Nesbit M, Herlyn M. Adhesion receptors in human melanoma progression. Invasion
Metastasis. 1994;14:131-146. PMID7657508
29. Shih IM, Herlyn M. Autocrine and paracrine roles for growth factors in melanoma. In Vivo.
1994;8:113-123. PMID7519892
30. Soballe PW, Daly JM, Herlyn M. Human carcinogenesis in SCID/human chimeras: a
cutaneous model. ACS Surgical Forum. 1994;65:559-561.
31. Herlyn M, Satyamoorthy K. Activated ras: yet another player in melanoma? Am J Pathol.
1996;149:739-744. PMID8780377 (PMC1865164)
32. Satyamoorthy K, Nesbit M, Hsu M-Y, Herlyn M. Utility of adenoviruses as gene
expression modules in melanoma. Biomedical and Health Res. 1996;12:71-77.
33. Hsu M-Y, Herlyn M. Cultivation of normal human epidermal melanocytes. In: Jones GE,
ed. Methods in Molecular Medicine: Human Cell Culture Protocols. Totowa, NJ: Humana
Press; 1996:9-20.
34. Smalley KSM, Herlyn M. Towards the targeted therapy of melanoma. Mini-Rev Med
Chem. 2006;6:109-120.
35. Satyamoorthy K, Herlyn M. Melanoma: molecular and cellular abnormalities. In: Bertino
JR, ed. Encyclopedia of Cancer II. San Diego, CA: Academic Press; 1997:1042-1050.
36. Sauter ER, Herlyn M. Molecular biology of human melanoma development and
progression. Mol Carcinog. 1998;23:132-143. PMID9833774
37. Meier F, Satyamoorthy K, Nesbit M, Hsu M-Y, Schittek B, Garbe C, Herlyn M. Molecular
events in melanoma development and progression. Front Biosci. 1998;3:D1005-1010.
PMID9740553
38. Kamb A, Herlyn M. Malignant melanoma. In: Vogelstein B, Kinzler KW, eds. The Genetic
Basis of Human Cancer. New York, NY: McGraw-Hill Co.; 1998:507-518.
39. Nesbit M, Seatluri V, Herlyn M. Biology of melanocytes and melanoma. In: Balch C,
Houghton A, Sober AJ, Soong S, eds. Cutaneous Melanoma. St. Louis, MO: Quality
Medical Publishing; 1998:463-473.
40. Satyamoorthy K, Meier F, Hsu M-Y, Berking C, Herlyn M. Human xenografts, human skin
and skin reconstructs for studies in melanoma development and progression. Cancer
Metastasis Rev. 1999;18:401-405. PMID10721493
41. Hsu M-Y, Elder DE, Herlyn M. Melanoma: the Wistar melanoma (WM) cell lines. In:
Masters JRW, Palsson B, eds. Human Cell Culture, Vol. 3. London: Kluwer Academic
Publishing; 2000:259-274.
42. Herlyn M, Berking C, Li G, Satyamoorthy K. Lessons from melanocyte development for
understanding the biological events in naevus and melanoma formation. Melanoma Res.
2000;10:303-312. PMID10985664
43. Li G, Herlyn M. Dynamics of intercellular communication during melanoma development.
Mol Med Today. 2000;6:163-169. PMID10740255
44. Cascinelli N, Herlyn M, Schneeberger A, Kuwert C, Slominski A, Armstrong C, Belli F,
Lukiewcz S, Maurer D, Ansel J, Stingl G, Saida T. What is the most promising strategy for
the treatment of metastasizing melanoma? Exp Dermatol. 2000;9:439-451.
35
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
45. Herlyn M, Satyamoorthy K. Molecular biology of cutaneous melanoma. In: DeVita VTJ,
Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 6th ed.
Philadelphia, PA: Lippincott Williams & Wilkins; 2000:2003-2012.
46. Berking C, Herlyn M. Human skin reconstruct models: a new application for studies of
melanocyte and melanoma biology. Histol Histopathol. 2001;16:669-674. PMID11332722
47. Satyamoorthy K, Bogenrieder T, Herlyn M. No longer a molecular black box—new clues
to apoptosis and drug resistance in melanoma. Trends Mol Med. 2001;7:191-194.
PMID11325619
48. Gruss C, Herlyn M. Role of cadherins and matrixins in melanoma. Curr Opin Oncol.
2001;13:117-123. PMID11224709
49. Berking C, Herlyn M. Experimental inductin of human atypical melanocytic lesions and
melanoma in ultraviolet-irradiated human skin grafted to immunodeficient mice. Methods
Mol Med. 2001;61:71-84. PMID22323252
50. Kamb A, Herlyn M. Malignant melanoma. In: Scriver CR, Beaudet AL, Sly WS, Valle D,
eds. The Metabolic and Molecular Bases of Inherited Disease. New York, NY: McGrawHill Co.; 2001:967-977.
51. Hsu M-Y, Meier F, Herlyn M. Melanoma development and progression: a conspiracy
between tumor and host. Differentiation. 2002;70:522-536. PMID12492494
52. Herlyn M, Padarathsingh M, Chin L, Hendrix M, Becker D, Nelson M, DeClerck Y,
McCarthy J, Mohla S. New approaches to the biology of melanoma: a workshop of the
National Institutes of Health Pathology B Study Section. Am J Pathol. 2002;161:19491957. PMID12414540
53. Bogenrieder T, Herlyn M. Cell-surface proteolysis, growth factor activation and
intercellular communication in the progression of melanoma. Crit Rev Oncol Hematol.
2002;44:1-15. PMID12398996
54. Satyamoorthy K, Herlyn M. Cellular and molecular biology of human melanoma. Cancer
Biol Ther. 2002;1:14-17. PMID12170758
55. Li G, Satyamoorthy K, Herlyn M. Dynamics of cell interactions and communications
during melanoma development. Crit Rev Oral Biol Med. 2002;13:62-70. PMID12097238
56. Ruiter D, Bogenrieder T, Elder D, Herlyn M. Melanoma-stroma interactions: structural and
functional aspects. Lancet Oncol. 2002;3:35-43. PMID11905603
57. Herlyn M. Emerging concepts and technologies in melanoma research. Melanoma Res.
2002;12:3-8. PMID11828252
58. Herlyn M, Guerry D. First international melanoma research congress. Cancer Biol Ther.
2003;2:721-724. PMID14688485
59. Smalley KS, Herlyn M. The great escape: another way for melanoma to leave
physiological control? J Invest Dermatol. 2003;121:xi-xii. PMID14632176
60. Bogenrieder T, Herlyn M. Axis of evil: molecular mechanisms of cancer metastasis.
Oncogene. 2003;22:6524-6536. PMID14528277
61. Tuveson DA, Weber BL, Herlyn M. BRAF as a potential therapeutic target in melanoma
and other malignancies. Cancer Cell. 2003;4:95-98. PMID12957284
62. Liu ZJ, Herlyn M. Slit-Robo: neuronal guides signal in tumor angiogenesis. Cancer Cell.
2003;4:1-2. PMID12892705
63. Marincola FM, Wang E, Herlyn M, Seliger B, Ferrone S. Tumors as elusive targets of Tcell-based active immunotherapy. Trends Immunol. 2003;24:335-342. PMID12810110
64. Li G, Satyamoorthy K, Meier F, Berking C, Bogenrieder T, Herlyn M. Function and
regulation of melanoma-stromal fibroblast interactions: when seeds meet soil. Oncogene.
2003;22:3162-3171. PMID12789292
65. Velazquez OC, Herlyn M. The vascular phenotype of melanoma metastasis. Clin Exp
Metastasis. 2003;20:229-235. PMID12741681
36
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
66. Satyamoorthy K, Herlyn M. p16INK4A and familial melanoma. Methods Mol Biol.
2003;222:185-195. PMID12710687
67. Haass NK, Smalley KSM, Herlyn M. The role of altered cell-cell communication in
melanoma progression. J Mol Histol. 2004;35:309-318. SPRINGER35354
68. Perlis C, Herlyn M. Recent advances in melanoma biology. Oncologist. 2004;9:182-187.
PMID15047922
69. Haass NK, Smalley KS, Li L, Herlyn M. Adhesion, migration and communication in
melanocytes and melanoma. Pigment Cell Res. 2005;18:150-159. PMID15892711
70. Meier F, Schittek B, Busch S, Garbe C, Smalley K, Satyamoorthy K, Li G, Herlyn M. The
RAS/RAF/MEK/ERK and PI3K/AKT signaling pathways present molecular targets for the
effective treatment of advanced melanoma. Front Biosci. 2005;10:2986-3001.
PMID15970553
71. Hsu M-Y, Rovinsky S, Penmatcha S, Herlyn M, Muirhead D. Bone morphogenetic
proteins in melanoma: angel or devil? Cancer Metastasis Rev. 2005;24:251-263.
PMID15986135
72. Hsu M-Y, Li L, Herlyn M. Cultivation of normal human epidermal melanocytes in the
absence of phorbol esters. Methods Mol Med. 2005;107:13-28. PMID15492362
73. Fang D, Herlyn M. The transformed phenotype of melanocytes. In: Nordlund JI, Boissy
RE, Hearing VJ, King RA, Oetting WS, Ortonne J-P, eds. The Pigmentary System:
Physiology and Pathophysiology. 2nd ed. Madden, MA: Wiley-Blackwell; 2006:489-496.
74. Herlyn M. Molecular targets in melanoma: strategies and challenges for diagnosis and
therapy. Int J Cancer. 2006;118:523-526. PMID16258898
75. Smalley KS, Herlyn M. Targeting intracellular signaling pathways as a novel strategy in
melanoma therapeutics. Ann N Y Acad Sci. 2005;1059:16-25. PMID16382039
76. Haass NK, Herlyn M. Normal human melanocyte homeostasis as a paradigm for
understanding melanoma. J Investig Dermatol Symp Proc. 2005;10:153-163.
PMID16358819
77. Smalley KS, Lioni M, Herlyn M. Targeting the stromal fibroblasts: a novel approach to
melanoma therapy. Expert Rev Anticancer Ther. 2005;5:1069-1078. PMID16336098
78. Smalley KS, Brafford PA, Herlyn M. Selective evolutionary pressure from the tissue
microenvironment drives tumor progression. Semin Cancer Biol. 2005;15:451-459.
PMID16043361
79. Smalley KS, Herlyn M. Towards the targeted therapy of melanoma. Mini Rev Med Chem.
2006;6:387-393. PMID16613575
80. Cher ML, Towler DA, Rafii S, Rowley D, Donahue HJ, Keller E, Herlyn M, Cho EA, Chung
LWK. Cancer interactions with the bone environment: a workshop of the National
Institutes of Health Tumor Microenvironment Study Section. Am J Pathol. 2006;168:14051412. PMID1665160
81. Smalley KSM, Lioni M, Herlyn M. Life isn’t flat: taking cancer biology to the next
dimension. In Vitro Cellular & Develop Biol Animals. 2006;42:242-247. PMID17163781
82. Lee JT, Herlyn M. Microenvironment influences melanoma progression. J Cell Biochem.
2007;101:862-872. PMID17171636
83. Smalley KS, Herlyn M. Malignant melanoma. In: Scriver CR, Beaudet AL, Sly WS, Valle
D, eds. The Online Metabolic and Molecular Bases of Inherited Disease. Heidelberg:
Springer; 2007:1-27.
84. Pinnix CC, Herlyn M. The many faces of Notch signaling in skin-derived cells. Pigment
Cell Res. 2007;20:458-465. PMID17935489
85. Herlyn M, Halaban R, Ronai Z, Schuchter L, Berwick M, Pinkel D. Roadmap for new
opportunities in melanoma research. Semin Oncol. 2007;34:566-576. PMID18086289
37
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
86. Zabierowski S, Herlyn M. Role of stem cells in melanoma progression: hopes for a better
treatment. Expert Rev Dermatol. 2007;2:191-201.
87. Lee JT, Herlyn M. Old disease, new culprit: tumor stem cells in cancer. J Cell Physiol.
2007;213:603-609. PMID17873516
88. Gaddipati H, Herlyn M. Association of polymorphisms of FAS-1377, FAS-670, and FASL844 genes with risk factors for cutaneous malignant melanoma. Cancer J. 2007;13:226228. PMID1776275
89. Smalley KSM, Lioni M, Noma K, Haass NK, Herlyn M. In vitro three-dimensional tumor
microenvironment models for anticancer drug discovery. Expert Opinion Drug Discov.
2008;3:1-10. (PMC N/A)
90. Zabierowski SE, Herlyn M. Melanoma stem cells: the dark seed of melanoma. J Clin
Oncol. 2008;26:2890-2894. PMID18539969 (PMC N/A)
91. Roesch A, Herlyn M. Melanoma stem cells. In: Farrar W, ed. Cancer Stem Cells.
Cambridge University Press; 2010:1-48. (PMC N/A)
92. Haass NK, Hoeller C, Herlyn M. Targeting signaling pathways—in the search of
melanoma’s Achilles’ heel. In: Bar-Eli M, ed. Regulation of Gene Expression in the Tumor
Environment. Springer; 2008:27-42. (PMC N/A)
93. Villanueva J, Herlyn M. Melanoma and the tumor microenvironment. Curr Oncol Rep.
2008;10:439-446. PMID18706274 (PMC N/A)
94. Smalley K, Herlyn M. Integrating tumor-initiating cells into the paradigm for melanoma
targeted therapy. Int J Cancer. 2009;124:1245-1250. PMID19089923 (PMC N/A)
95. Villanueva J, Herlyn M. Melanoma. In: Encyclopedia of Life Sciences (eLS). John Wiley &
Sons; 2009. (PMC N/A)
96. Santiago-Walker A, Li L, Herlyn M. Melanocytes: from morphology to application. Skin
Pharmacol Physiol. 2009;22:114-121. PMID19188759 (PMC N/A)
97. Herlyn M. Driving in the melanoma landscape. Exp Dermatol. 2009;18:506-508.
PMID19366372 (PMC N/A)
98. Fukunaga-Kalabis M, Santiago-Walker A, Herlyn M. Matricellular proteins produced by
melanocytes and melanomas: in search for functions. Cancer Microenvironment.
2008;1:93-102. PMID19308688 (PMC2654351)
99. Zabierowski SE, Herlyn M. Embryonic stem cells as a model to study melanocyte
development. Methods Mol Biol. 2010;584:301-316. PMID19907984 (PMC N/A)
100. Gaddipati H, Herlyn M. Melanoma: mutations in multiple pathways at the tumor-stroma
interface. In: Thomas-Tikhoenenko A, ed. Cancer Genome and Tumor Microenvironment.
New York, NY: Springer, 2010; 455-470. (PMC N/A)
101. Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M. Dermis-derived stem cells: a
source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res.
2011;24:422-429. PMID21410654 (PMC N/A)
102. Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step
towards manageable disease. Clin Cancer Res. 2011;17:1658-1663. PMID21447722
(PMC3079374)
103. Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance
cells. J Invest Dermatol. 2011;131:1600-1604. PMID21654838 PMC(3471358)
104. Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms
and future treatment options. Cancer Res. 2011;71:7137-7140. PMID22131348
(PMCID3588168)
105. Zhang G, Herlyn M. Tumor microenvironment for melanoma cells. In: Bosserhoff A, ed.
Melanoma Development. New York: Springer; 2011:297-308. (PMC N/A)
106. Herlyn M, Villanueva J. Sorting through the many opportunities for melanoma therapy.
Pigm Cell Melanoma Res. 2011;24:975-7. PMID21899726 (PMC N/A)
38
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
107. Zabierowski SE, Baubet V, Himes B, Li L, Fukunaga-Kalabis M, Patel S, McDaid R,
Guerra M, Gimotty P, Dahmane N, Herlyn M. Direct reprogramming of melanocytes to
neural crest stem-like cells by one defined factor. Stem Cells. 2011;1752-62.
PMID21948558 (PMC3615703)
108. Li L, Fukunaga-Kalabis M, Herlyn M. Isolation and cultivation of dermal stem cells that
differentiate into functional melanocytes. Methods Mol Biol. 2012;806:15-29.
PMID22057442 (PMC N/A)
109. Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer
Biomark. 2011;9:267-286. PMID22112480 (PMC N/A)
110. Lee JT, Herlyn M. MEK’ing the most of p53 reactivation therapy in melanoma. J Invest
Dermatol. 2012;132:263-265. PMID22241441 (PMC N/A)
111. Slipcevic A, Herlyn M. Narrowing the knowledge gaps for melanoma. Upsala J Med Sci.
2012;117:237-243. PMID22339359 (PMC3339555)
112. Maurer M, Somasundaram R, Herlyn M, Wagner SN. Immunotargeting of tumor
subpopulations in melanoma patients: a paradigm shift in therapy approaches.
Oncoimmunology. 2012;1:1454-1456. PMID23243627 (PMC3518536)
113. Somasundaram R, Villanueva J, Herlyn M. Intratumoral heterogeneity as a therapy
resistance mechanism: role of melanoma subpopulations. Advances Pharmacol.
2012;65:335-359. PMID2259031 (PMC in Process by Elsevier)
114. Facombre N, Nakagawa H, Herlyn M, Basu D. Stem-like therapy and therapy resistance
in squamous cell carcinoma. Advances in Pharmacol. 2012;65:359-365. PMID22959028
(PMC in Process by Elsevier)
115. Swoboda R, Herlyn M. There is a world beyond proteIn mutations: the role of nonocoding
RNAs in melanomagenesis. Exp Dermatol. 2013;22:303-306. PMID23489578
(PMC3637432 [Available on 2014/5/1]; NIHMS445771)
116. Li L, Fukunaga-Kalabis M, Herlyn M. Isolation, characterization and differentiation of
human multi- potent dermal stem cells. Methods Mol Biol. 2013;989:235-246.
PMID234838399
117. Merlino G, Flaherty K, Acquavella N, Day CP, Aplin A, Homen S, Topalian S, Van Dyke T,
Herlyn M. The future of preclinical mouse models in melanoma treatment is now. Pigm
Cell Mel Res. 2013;26:E8-E14. PMID23531109
118. Slipicevic A, Somasundaram S, Sproesser K, Herlyn M. Isolation of melanoma
subpopulations using negative selection. Methods Mol Biol. 2014;1102:501-512.
PMID24258995
Research Publications, Non-Peer Reviewed
1. Guerry D, Alexander MA, Fuhrer JP, Herlyn M, Mitchell KF. HLA-DR-dependent
autologous T-cell proliferation induced by cultured primary melanoma. In: Seji M, ed.
Phenotypic Expression in Pigment Cells. Tokyo, Japan: University of Tokyo Press;
1981:547-553.
2. Mach JP, Forni M, Buchegger F, Carrel S, Ritschard J, Donath A, Herlyn M, Koprowski H.
Use of radiolabeled monoclonal antibodies against colon carcinoma for photoscanning
detection of tumors in patients. In: Raynaud C, ed. Nuclear Medicine and Biology IV.
Paris, France: Pergamon Press; 1982: 2292-2294.
3. Holgersson J, Karlsson KA, Karlsson P, Ringqvist M, Stromberg N, Thurin J, Blaszczyk
M, Herlyn M, Steplewski Z, Koprowski H. Mouse monoclonal antibodies with specificity for
human melanoma cells are directed against hitherto unknown disialogangliosides. In:
Chester MA, Heinegard D, Lundblad A, Svensson S, eds. Glycoconjugates. LundRonneby, Sweden: Rahms; 1983:856-858.
39
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.
16.
17.
18.
19.
Herlyn M, Blaszczyk M, Koprowski H. Immunodiagnosis of human solid tumors. In:
Riethmueller G, Koprowski H, Kleinst SV, Munk K, eds. Genes and Antigens in Cancer
Cells: The Monoclonal Antibody Approach, Vol. 19. Basel, Switzerland: S Karger
Publications; 1984:160-170.
DeFreitas E, Suzuki H, Herlyn D, Lubeck M, Sears H, Herlyn M, Koprowski H. Human
antibody induction to the idiotypic and anti-idiotypic determinants of a monoclonal
antibody against a gastrointestinal carcinoma antigen. Curr Top Microbiol Immunol.
1985;75-89.
Herlyn M, Koprowski H. New tumor markers in human gastrointestinal cancer. In:
Nakamura R, Vito WR, Tucker ESI, eds. Clinical Laboratory Molecular Analyses: New
Strategies in Autoimmunity, Cancer and Virology. San Diego, CA: Grune and Stratton;
1985:129-143.
Herlyn M. Tumor markers in human colorectal carcinoma. In: Clinical Laboratory
Molecular Analyses: Future Directions. San Diego, CA: Scripps Clinic and Research
Foundation; 1985:86-92.
Herlyn M. Detection of tumor-associated antigens in sera of patients with early
gastrointestinal malignancies. In: Chatal JF, Danis M, eds. Monoclonal Antibodies in
Oncology: Clinical Application. Nantes, France: Nouvelles Editions Medicales Francaises;
1985:21-24.
Steplewski Z, Blaszczyk M, Herlyn D, Herlyn M, Koprowski H. Effector cells in ADCC with
anti-breast cancer monoclonal antibodies. In: Ceriani RL, ed. Workshop on Monoclonal
Antibodies and Breast Cancer. San Francisco, CA: Martinus Nijhoff Publishing; 1985:134149.
Herlyn M, Steplewski Z, Herlyn D, Koprowski H. CO 17-1A and related monoclonal
antibodies: their production and characterization. Hybridoma. 1986;5(suppl 1):S3-10.
PMID3744383
Clark WHJ, Herlyn M. Melanocyte differentiation. Lab Invest. 1987;57:600-601.
Herlyn M, Ross AH, Balaban G, Herlyn D, Thurin J, Rodeck U, Koprowski H. Cell biology
of melanoma and nonmalignant melanocytic lesions. In: Mackie RM, ed. Pigment Cell:
Pathobiology of Melanoma. Karger, Basel, Switzerland; 1987:166-181.
Kath R, Rodeck U, Menssen HD, Mancianti ML, Linnenbach AJ, Elder DE, Herlyn M.
Tumor progression in the human melanocytic system. Anticancer Res. 1989;9:865-872.
PMID2554787
Mancianti ML, Herlyn M. Tumor progression in melanoma: the biology of epidermal
melanocytes in vitro. Carcinog Compr Surv. 1989;11:369-386. PMID2646021
Györfi T, Rodeck U, Herlyn M. Growth factors in melanoma. In: Biological Agents in the
Treatment of Melanoma and Other Cancers; 1990:501-510; Proceedings of the
International Conference, Newcastle, Australia.
Juhasz I, Herlyn M. Stage-related structures on melanoma cells. In: Hersey P, ed.
Biological Agents in the Treatment of Melanoma and Other Cancers; 1990:256-267;
Proceedings of the International Conference, Newcastle, Australia.
Rodeck U, Herlyn M. Growth regulation in normal and malignant melanocytes. In:
Paukovits WR, ed. CRC Uniscience: Growth Regulation and Carcinogenesis. Boca
Raton, FL: CRC Press; 1990:243-250.
Graeven U, Becker D, Herlyn M. Structural and functional characteristics of human
melanoma. In: Pretlow TG, Pretlow TP, eds. Biochemical and Molecular Aspects of
Selected Cancers. Orlando, FL: Academic Press; 1991:151-176.
Herlyn M, Houghton AN. Biology of melanocytes and melanoma. In: Balch C, Houghton
A, Milton G, Sober A, eds. Cutaneous Melanoma. Philadelphia, PA: Lippincott Co.;
1991:82-92.
40
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
20. Litwack G, Robertson NM, Maksymowych AB, Herlyn M. Vitamin B6 and other inhibitors
of glucocorticoid receptor function and cell-death of B16 melanoma cells. In: Jacobs MM,
ed. Vitamins and Minerals in the Prevention and Treatment of Cancer. Boca Raton, FL:
CRC Press; 1991:19-30.
21. Valyi-Nagy I, Rodeck U, Kath R, Mancianti ML, Clark WH, Herlyn M. The human
melanocyte system as a model for studies on tumor progression. Basic Life Sci.
1991;57:315-326, discussion 326-318. PMID1814292
22. Houghton AN, Herlyn M, Ferrone S. Melanoma antigens. In: Balch C, Houghton A, Milton
G, Sober A, eds. Cutaneous Melanoma. Philadelphia, PA: Lippincott Co; 1992:130-143.
23. Miller EJ, Herlyn M. The basement membrane in benign and malignant melanocytic
lesions. In: Rabes H, Peters PE, Karger S, Munk K, eds. Contributions to Oncology.
Basel, Switzerland: Karger; 1992:269-282.
24. Herlyn M. Molecular biology of the melanoma cell surface - translational opportunities.
Hem/Onc Annals. 1993;1:251-255.
25. Györfi T, Herlyn M. Melanocyte and melanoma cell lines. In: Hay RJ, ed. The Atlas of
Human Tumor Cell Lines. San Diego, CA; Academic Press; 1994:413-428.
26. Herlyn M. Molecular genetics, immunology and experimental pathology of melanoma.
Report presented at: International Melanoma Conference; Brisbane, Australia: April 6-9,
1994. Melanoma Res. 1994;4:331-336. PMID7858419
27. Herlyn M, Schuchter L. Gene therapy of melanoma: strategies and perspectives. Skin
Cancer J. 1996;14:92-93.
28. Puri N, Herlyn M. Melanoma: effects of growth factors. In: Miller SJ, Maloney ME, eds.
Cutaneous Oncology: Pathophysiology, Diagnosis, and Treatment. Cambridge, MA:
Blackwell Sci Inc.; 1996.
29. Dignat-George F, Bardin N, Combes V, Figarella-Branger D, Frances V, Herlyn M,
Johnson JP, Lepidi H, Mutin M, Vewton J, Pickl WF, Schneemann M, Simmons D, Simoni
J, Sampol J. CD146 (S-ENDO/Muc18). In: Kishimoto T, Goyert S, Kikutani H, et al, eds.
Leucocyte Typing VI: White Cell Differentiation Ags. New York, NY: Garland Publishing
Inc.; 1997:755-759.
30. Steplewski Z, Blaszczyk M, Herlyn D, Herlyn M, Koprowski H. Effector cells in ADCC with
anti-breast cancer monoclonal antibodies. In: Ceriani RL, ed. Monoclonal Antibodies and
Breast Cancer. Hingham, MA: Martinus Nijhoff Publishing; 1997:134-139.
31. Herlyn M. Endothelial cells as targets for tumor therapy. J Immunother. 1999;22:185.
PMID10335478
32. Berking C, Herlyn M. The role of UV in melanomagenesis. In: Ortonne J-P, Ballotti R, eds.
Mechanisms of Sun Tanning. London, England: Martin Dunitz Publications; 2002:327332.
33. Bogenrieder T, Elder DE, Herlyn M. Molecular and cellular biology. In: Balch CM,
Houghton AN, Sober AJ, Soong S-J, eds. Cutaneous Melanoma. 4th ed. St. Louis, MO:
Quality Medical Publications; 2003:713-751.
34. Ruiter GJ, Herlyn M. [Melanoma-stroma interactions and melanoma progression]. J Dtsch
Dermatol Ges. 2003;1:773-776.
35. Smalley KS, Herlyn M. Loitering with intent: new evidence for the role of BRAF mutations
in the proliferation of melanocytic lesions. J Invest Dermatol. 2004;123:xvi-xvii.
PMID15373800
36. Brafford P, Herlyn M. Gene expression profiling of melanoma cells−searching the
haystack. J Transl Med. 2005;3:2. PMID15649323 (PMC545940)
37. Herlyn M. Metatastic melanoma cells: introduction. Cancer Metastasis Rev. 2005;24:193194. PMID15986131
41
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
38. Li G, Herlyn M. Information sharing and collateral damage. Trends Mol Med.
2005;11:350-352. PMID16002338
39. Liu ZJ, Herlyn M. Molecular biology of cutaneous melanoma. In: DeVita VTJ, Hellman S,
Rosenberg SA, eds. 7th ed. Cancer: Principles and Practice of Oncology. Philadelphia,
PA: Lippincott Williams & Wilkins; 2005:1745-1753.
40. Pinnix CC, Kogan M, Herlyn M. Melanoma stem cells: have we overlooked them? Mel
Letter. 2005;23:3-4.
41. Lee JT, Herlyn M. Preventing metastasis: a LOX to learn. Cellscience Rev. 2006;3.
42. Lee JT, Herlyn M. Embryogenesis meets tumorigenesis. Nature Med. 2006;12:882-884.
PMID16892028
43. Smalley KSM, Herlyn M. Is knowledge about the genetic and epigenetic alterations in
melanoma a basis for targeted therapy? Exp Dermatol. 2007;15:844-845.
44. Smalley KSM, Herlyn M, Flaherty KT. Targeting BRAF/MEK inhibitors in melanoma
therapy: new hope or another false dawn? Exp Rev Derm. 2007;2:179-190.
45. Herlyn M. Farming cells to rebuild skin and melanoma. Cancer Biol Ther. 2007;6:467-471.
PMID17374983
46. Fukunaga-Kalabis M, Li L, Herlyn M. Three-dimensional culture of human skin. AACR
Educational Book from the AACR Annual Meeting; 2007:203-206.
47. Fukunaga-Kalabis M, Herlyn M. Unraveling mysteries of the multifunctional protein
SPARC. J Invest Dermatol. 2007;127:2497-2498. PMID17934501
48. Basu D, Herlyn M. Salmonella Typhimurium and a novel RNA interference vector for
cancer gene therapy. Cancer Biol Therap. 2008;7:151-152. PMID18347415 (PMC N/A)
49. Zabierowski SE, Herlyn M. Learning the ABCs of melanoma-initiating cells. Cancer Cell.
2008;13:185-187. PMID18328422 (PMC N/A)
50. Possik P, Lee JT, Herlyn M. Transforming the melanocyte: more than just MAPK.
Bioforum Eur. 2008;2:1-3. (PMC N/A)
51. Lee JT, Brafford P, Herlyn M. Unraveling the mysteries of IGF-1 signaling in melanoma. J
Invest Dermatol. 2008;128:1358-1360. PMID18478012 (PMC N/A)
52. Vultur A, Herlyn M. Cracking the system: melanoma complexitiy demands new
therapeutic approaches. Pigm Cell Mel Res. 2009;22:4-5. PMID19054340 (PMC N/A)
53. Passague E, Rafii S, Herlyn M. Cancer stem cells are everywhere. Nature Med.
2009;15:23. PMID19129778 (PMC N/A)
54. Basu D, Herlyn M. Defining microenvironments within mouse models that enhance tumor
aggressiveness. Cancer Biol Ther. 2009;8:4. PMID19182538 (PMC N/A)
55. Fisher DE, Barnhill R, Hodi FS, Herlyn M, Merlino G, Medrano E, Bastian B, Landi MT,
Sosman J. Melanoma from bench to bedside. Meeting report from the 6th International
Melanoma Research Congress. Pigm Cell Mel Res. 2010;23:14-26. PMID20025711
(PMC N/A)
56. Herlyn M, Fukunaga-Kalabis M. What is a good model for melanoma? J Invest Dermatol.
2010;130:911-912. PMID20231823 (PMC N/A)
57. Santiago-Walker A, Herlyn M. The ups and downs of transcription factors in melanoma. J
Natl Cancer Inst. 2010;102:1103-1104. PMID20660367 (PMC N/A)
58. Vultur A, Villanueva J, Herlyn, M. BRAF inhibitor unveils its potential against advanced
melanoma. Cancer Cell. 2010;18:301-302. (PMC N/A)
59. Herlyn M, Nathanson, K. Taking the guesswork out of uveal melanoma. New Engl J Med.
2010;263:2256-2257. PMID21083377 (PMC N/A)
60. Herlyn M, Bastian B. Pigm Cell Mel Res. 2010;23:834. PMID20973934 (PMC N/A)
61. Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv
eradicate melanoma? Mol Ther. 2011;19:638-640. PMID21455210 (PMC3070110)
42
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
62. Herlyn M. New dream team for melanoma therapy. Pigm Cell Mel Res. 2012;25:279-280.
PMID22462086 (PMC N/A)
63. Somasundaram R, Herlyn M. Melanoma exosomes: messengers of metastasis. Nature
Med. 2012;18:853-854. PMID22673991 (PMC N/A)
64. Herlyn M. Randy Lomax - the passionate melanoma advocate and champion of the
Melanoma Research Foundation. Pigm Cell Mel Res. 2012;25:832-833. PMID22702393
(PMC N/A)
65. Räsänen K, Herlyn M. Paracrine signaling between carcinoma cells and mesenchymal
stem cells generates cancer stem cell niche via epithelial-mesenchymal transition. Cancer
Discov. 2012;2:775-779. PMID22969117 (PMC in Process by AACR)
66. Fukunaga-Kalabis M, Herlyn M. Beyond ABC: another mechanisms of drug resistance in
melanoma side population. J Invest Dermatol. 2012;132:2317-2319. PMID22971921
(PMC in Process)
67. Zhang G, Herlyn M. Human nevi: no longer precursors of melanomas? J Invest Dermatol.
2012;132:2133-2134. PMID22895446 (PMC N/A)
69. Fukunaga-Kalabis M, Herlyn M. Cancer: complexion matters. Nature. 2012;491:342-343.
PMID23123853 (PMC N/A)
70. Somasundaram R, Herlyn M. Relapse of melanoma after successful adoptive T-cell
therapy: escape through inflammation-induced phenotypic melanoma plasticity. Pigm Cell
Mel Res. 2013;26:2-4. PMID23387000 (PMC N/A)
71. Wang T, Somasundaram R, Herlyn M. Combination therapy of immunocytokines with
Ipilumumab: a cure for melanoma? J Invest Dermatol. 2013;133:595-596. PMID23399823
(PMC N/A)
72. Wang T, Herlyn M. The macrophage: a new factor in UVR-induced melanomagenesis. J
Invest Dermatol. 2013;133:1711-1713. PMID23760048
73. Vultur A, Herlyn M. Snapshot: melanoma. Cancer Cell. 2013;23:706. PMID23680152
Books
Herlyn M. Molecular and Cellular Biology of Melanoma. Austin, TX: R.G. Landes Co; 1993.
PATENTS
1. Detection of Colorectal Carcinoma
U.S. Patent #4,471,057
Issued:
September 11, 1984
Inventors: Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn
2.
Lewis Blood Group Phenotype Assay
U.S. Patent #4,607,009
Issued:
August 19, 1986
Inventors: Zenon Steplewski, Hilary Koprowski, and Meenhard Herlyn
3.
Monoclonal Anti-Ornithine Decarboxylase Antibody and Method of Producing
Same
U.S. Patent #4,637,984
Issued:
January 20, 1987
Inventors: Thomas O’Brien, Anthony Pegg, and Meenhard Herlyn
4.
Diagnostic Method for Detection of Neural Crest Disease
U.S. Patent #4,786,593
Issued:
November 22, 1988
43
Curriculum Vitae for Meenhard Herlyn, D.V.M., D.Sc.
Inventors: Alonzo Ross, Hilary Koprowski, and Meenhard Herlyn
5.
Monoclonal Antibodies against Melanoma-Associated Antigens and Hybrid Cell
Lines Producing These Antibodies and Use Thereof
U.S. Patent #4,849,509
Issued:
July 18, 1989
Inventors: Jan Thurin, Hilary Koprowski, Zenon Steplewski, and Meenhard Herlyn
6.
Monoclonal Antibody to EGF Receptor
U.S. Patent #5,470,571
Issued:
November 28, 1995
Inventors: Meenhard Herlyn and Ulrich Rodeck
7.
WT1 Monoclonal Antibodies and Methods of Use Thereof
U.S. Patent #5, 622,835
Issued:
April 22, 1997
Inventors: Meenhard Herlyn, Frank Rauscher, Ulrich Rodeck, and Jennifer Morris
8.
Methods for Inducing Localized Vascular Development and Enhancing the Repair
of a Wound in the Mammalian Dermis
U.S. Patent #6,486,133
Issued:
November 26, 2002
Inventors: Meenhard Herlyn, Mark Nesbit, and Kapaettu Satyamoorthy
9.
Organotypic Culture of Colon and Usage Thereof
U.S. Patent #7,217,570
Issued:
May 15, 2007
Inventors: Meenhard Herlyn and Jiri Kalabis
10. Multipotent Adult Stem Cells
U.S. Patent #60/671,025
Issued:
2005
Inventors: Xiao-Wei Xu, Hong Yu, Doug Fang, Meenhard Herlyn
11. Methods and Composition for Monitoring Cell Migration and Identifying Clinically
Relevant Cytotoxic T Lymphocyte Activity
U.S. Patent #7,544,465
Issued:
June 9, 2009
Inventors: Dorothee Herlyn, Meenhard Herlyn
12. Method for Dedifferentiating Melanocytes
PCT Application No PCT/US2009/058950
Issued:
September 30, 2009
Inventors: Meenhard Herlyn and Susan Zabierowski
13. Compositions Containing JARID1B Inhibitors and Methods for Treating Cancer
PCT Application No: 61/232,069
Issued:
August 7, 2009
Inventors: Meenhard Herlyn and Alexander Roesch
44